nach oben

Erschienen in:

Open Access 19.02.2021 | Special Report

Kidney biopsy guidebook 2020 in Japan

verfasst von: Yoshifumi Ubara, Takehiko Kawaguchi, Tasuku Nagasawa, Kenichiro Miura, Takayuki Katsuno, Takashi Morikawa, Eiji Ishikawa, Masao Ogura, Hideki Matsumura, Ryota Kurayama, Shinsuke Matsumoto, Yuhji Marui, Shigeo Hara, Shoichi Maruyama, Ichiei Narita, Hirokazu Okada, Kazuhiko Tsuruya, Committee of Practical Guide for Kidney Biopsy 2020

Erschienen in: Clinical and Experimental Nephrology | Ausgabe 4/2021

In 2020, Japanese Society of Nephrology established Committee of Practical Guide for Kidney Biopsy 2020, which published in (Jinseiken guidebook, 2020, vol. 2, page 1–180). This is the English version of that report.

A correction to this article is available online at https://doi.org/10.1007/s10157-021-02120-w.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

APTT

Activated partial thromboplastin time

ANCA

Antineutrophil cytoplasmic antibody

Blood pressure

CKD

Chronic kidney disease

Computed tomography

DKD

Diabetic kidney disease

ds-DNA

Double-stranded DNA antibodies

Diabetes mellitus

Electron microscopy

EGPA

Eosinophilic granulomatosis with polyangiitis

EB virus

Epstein–Barr virus

EBER

Epstein–Barr virus-encoded small RNA

FDP

Fibrin/fibrinogen degradation products

FSGS

Focal segmental glomerulosclerosis

GBM

Glomerular basement membrane

GPA

Granulomatosis with polyangiitis

HBV

Hepatitis B virus

HCV

Hepatitis C virus

HUS

Hemolytic-uremic syndrome

HIV

Human immunodeficiency virus

Immunofluorescence microscopy

ISH

In situ hybridization

Light microscopy

MRI

Magnetic resonance imaging

MPA

Microscopic polyangiitis

Membranous nephropathy

MCNS

Minimal change nephrotic syndrome

NAG

N-Acetyl-β-d-glucosaminidase

Prothrombin time

PCR

Polymerase chain reaction

RNP

Anti ribonucleoprotein antibody

Selectivity index

Anti-Smith (anti-Sm) antibody

SLE

Systemic lupus erythematosus

TMA

Thrombotic microangiopathy

TTP

Thrombotic thrombocytopenic purpura

TAFRO

Thrombocytopenia, anasarca, myelofibrosis, renal dysfunction, and organomegaly

Ultrasonography

α1MG

α1-Microglobulin

β2MG

β2-Microglobulin

Overview

A kidney biopsy is performed for a treatment strategy of renal disease by pathologically diagnosing renal disease. Kidney biopsy is a reliable gold standard technique, but various complications are common when obtaining tissue from an abundant vascular kidney. During a biopsy, vasovagal reflexes, including cold sweat, discomfort, nausea, vomiting, hypotension, and bradycardia, can occur. Hemorrhagic complications after a biopsy are important; 89% of hemorrhagic complications have been reported to occur within 24 h. Therefore, a cooperation system including nurses and physicians by performing intravenous feeding and medication, while performing electrocardiogram monitoring and oxygen saturation monitoring, is necessary.

Therefore, it is necessary to always take the benefits and risks of kidney biopsy into consideration and decide if there is an indication for kidney biopsy.

The conventional criteria for the indication of kidney biopsy for adults are shown in Table 1, according to previous reports [1‐3]. However, there is an opinion that it is necessary to extend these indications [3]. The following opinions were sent by a member of the Japanese Society of Nephrology.

There is an indication for kidney biopsy beyond the above indication. The indication must be considered in every case. It is important that it does not limit the experience-rich institutional practice.
Nephrologists, including young doctors with little experience in kidney biopsy, should recognize the safety procedures that are necessary to prevent the threshold to high-risk clinical conditions from lowering.
Cases of serious complications such as bleeding can happen, and the appropriate security guidelines for treatment should be prepared before a kidney biopsy.

Table 1

The conventional criteria for the indication of the kidney biopsy for adults

1. Glomerular hematuria with any degree of proteinuria

2. Isolated proteinuria > 1 g/day(or g/gCr)

3. Unexplained renal disease or intrinsic acute kidney injury

4. Renal manifestation related to systemic disease

The clinical treatment of renal disease is possible without performing a kidney biopsy. However, many nephrologists should note that a higher-quality clinical treatment is enabled by performing kidney biopsy.

The final decision of whether you perform kidney biopsy should be decided based on each institution’s guidelines and should be judged for every individual patient carefully. With respect to the decision, it is necessary to be performed based on the concept of “shared decision making: SDM,” after each attending physician explains the need and the risk of kidney biopsy to each patient thoroughly. We have provided explanations in the ‘Kidney biopsy guidebook 2020 in Japan’ along with questions and answers based on the results of a questionnaire survey for kidney biopsy that was performed in Japan from 2015 through 2017 by the Committee of Practical Guide for Kidney biopsy [4, 5], while adding the outline of the first edition of 2004 [1].

Chapter 1: Indication for kidney biopsy (Table 2)

Table 2

Indication of kidney biopsy in adults

1. Isolated glomerular hematuria

2. Isolated proteinuria

3. Proteinuria and glomerular hematuria

4. Rapidly progressive glomerulonephritis

5. Intrinsic acute kidney injury

6. Systemic disease with a urinalysis abnormality

7. Systemic disease with renal dysfunction, and/or without urinalysis abnormality

8. Diabetes mellitus

9. Elderly renal disease

10. Hereditary renal disease

11. Repeated kidney biopsy

Systemic disease with renal dysfunction, but without a urinalysis abnormality, includes acute or chronic tubulointerstitial nephritis secondary to sarcoidosis, drug-related disease such as tyrosine kinase inhibitors and checkpoint inhibitors. IgG4-related nephritis, or hypercalcemic nephropathy by activated cholecalciferol. A high value of tubular impairment markers such as β2-microglobulin (β2MG), α1-microglobulin (α1MG), or N-acetyl-β-d-glucosaminidase (NAG) is characteristic.
Systemic lupus erythematosus without urinary abnormality is called silent lupus nephritis. Light microscopy of kidney biopsy is reported to show mild glomerular change with class I or class II on 74% of silent lupus nephritis according to ISN-RPS lupus nephritis classification, but immunofluorescent microscopy shows IgG and C1q stain, and electron microscopy shows electron-dense deposits in the mesangium or subepithelium, which are characteristic to lupus nephritis.
Systemic vasculitis, including MPA, GPA and EGPA, can be diagnosed by extrarenal complications such as fever, upper respiratory tract disease, lung disease, neuropathy, and positivity for ANCA, even though urinary abnormality is negative. For these patients, kidney biopsy is reported to show crescent formation or vasculitis of small arteries with a frequency of 69%, although extrarenal organ biopsy may not show any vasculitis [26‐29].

Chapter 2: Kidney biopsy for patients with a clinical condition of high risk for percutaneous native kidney biopsy

Overview

The following renal disease was contraindicated for percutaneous native kidney biopsy under the ultrasonic guidance in the previous edition of the guidebook because the risk of hemorrhagic complications after a kidney biopsy is very high, and renal tissue sampling necessary for diagnosis is not obtained [1] (Table 3). However, as biopsy techniques, by using a newer US device and automatic biopsy needle, improved safety, there have been several reported case series that required or enabled histological diagnosis by kidney biopsy [4]. Therefore, when the benefit is judged to exceed a risk, kidney biopsy is indicated for patients with a clinical condition of high risk. A kidney biopsy should be performed in institutions that can treat hemorrhagic complications. The following diseases are not absolute contraindicated anymore but are described as a renal disease with high risk by a question and answer method.

Table 3

Clinical condition of the high risk (equaling relative contraindication) for percutaneous native kidney biopsy under ultrasonic guidance

1. Solitary native kidney

2. Contracted kidneys, small hyperechoic kidneys or end-stage kidneys

3. Kidneys of anatomic abnormalities including horseshoe kidney, malrotation kidney and renal arterial aneurysm

4. Polycystic kidney disease

5. Hydronephrosis

6. Malignant nephrosclerosis related to hypertensive emergency and scleroderma renal crisis

7. Uncontrolled bleeding diathesis or severe thrombocytopenia

8. Pregnancy

9. Severe obesity

10. Renal mass including malignant neoplasma

11. Chronic anticoagulant therapy while taking antiplatelet or anticoagulant medication

12. Active renal or perirenal infection, or skin infection over the biopsy site

13. Inability to provide informed consent

14. Uncooperative patient or inability to follow instructions during biopsy

For patients on chronic anticoagulation, kidney biopsy usually cannot be selected.
Whether kidney biopsy is essential or necessary for diagnosis, prognosis, and/or management must be discussed in the conference conducted at the institute.
If anticoagulation is temporarily stopped (e.g., mechanical heart valves), the risk of thrombosis must be judged in consideration of an individual situation, often in consultation with hematology and cardiology.
If anticoagulation is continued, the risk for bleeding after kidney biopsy must be evaluated in consideration of an individual situation. Kidney biopsy should be performed in an institution with the facilities for emergency treatment [123‐125] (Table 4).

Table 4

Chronic anticoagulation and drug holiday before kidney biopsy including two types of options in Japan

Drug	Drug holiday
Antiplatelet medication
Ticlopidine	① 5–7 days, ② 10–14 days
Clopidogrel	① 5–7 days, ② 14 days
Cilostazol	① 1 day, ② 2–4 days
Icosapentaenoic acid	7–10 days
Beraprost	2–3 days
Sarpogrelate	1–2 days
Aspirin	① 3 days, ② 7–10 days
Dipyridamole	1–2 days
Prasugrel	① 5–7 days, ② 14 days
Anticoagulant medication
Heparin	1 day
Dalteparin	1 day
Warfarin	3–5 days (intravenous heparin)
Dabigatran	1–4 days
Edoxaban	1 day
Rivaroxaban	1 day
Apixaban	1–2 days (intravenous heparin)
Vasodilator
Limaprost	1 day
Coronary vasodilator
Dilazep hydrochloride	1 day

Overview

Kidney biopsy is a gold standard for renal disease diagnosis and is the testing that we cannot miss in renal disease practice. However, it is invasive testing, and adequate informed consent is necessary. With respect to the nephrologist, it is necessary to explain the possible complications by the testing procedures, including hemorrhagic complications, in addition to the benefits of kidney biopsy to the patients. With respect to the patients, it is important to consent to kidney biopsy based on their own intention after having understood the benefits (merits) and disadvantages (demerits) of kidney biopsy explained by a physician [126].

In Japan, informed consent is obtained before kidney biopsy, and kidney biopsy is performed after, as a general rule, having acquired an agreement by letter. In this issue, the informed consent is commented by a question and answer method.

Explanation document to the patients

We take some kidney tissue by using the needle with the core size of the ball-point pen, observe it with a microscope, and clarify a cause of renal disease occurring in kidney. If a cause of the illness is understood, we can suggest an optimal therapy. A procedure or an operation to take out kidney tissue is named kidney biopsy.

We put an indwelling needle for intravenous feeding in the blood vessel of the arm before testing. An antimicrobial agent and/or hemostatic are usually given before testing. When BP falls or you came to feel sick during testing, a drug is given through an indwelling needle.

We cancel your diet before the testing. This is because you come to feel sick, and you may vomit by the pressure from a back hemostasis.

There is the kidney at the position near a back. You lie on your face and the stomach. A renal place is confirmed by US. From the skin of the back surface to the renal surface, a local anesthetic is injected in place to prick with a needle. We cut about a 2–3 mm opening in the skin surface. This section may remain as a minimal wound subsequently.

The thickness of the needle taking the renal tissue is a core size of the ball-point pen, and the length is around 2 cm. When a needle is inserted, there is no pain, but there is the sense that the back is pushed. When the needle reaches the kidney, we signal you. Please hold your breath for 5-10 s. We take the renal tissue at that moment. You hear a clicking sound at the moment that we take the renal tissue. Because there is no pain, do not worry. We conduct this operation 2–4 times.

When kidney biopsy is completed, we exert pressure from the back for 10–15 min to stop bleeding.

The testing is completed in approximately 30 min. After testing, you turn over on your back. Rest is required in a bed for 6–24 h. Eating and drinking after the testing is performed lying down. Urination and the defecation are carried out on the bed, too. When urination is difficult, we may use a tube called a urethral catheter. After testing, fever may occur. The cause is considered absorption fever occurring when the hematoma that occurred after a biopsy is absorbed.

For 4 weeks from the next morning, walking is possible, but please avoid running up the stairs, and please avoid intense, laborious work to avoid exerting stress on the area that was affected by the procedure.

With respect to the method of kidney biopsy performed in Japan, an automatic biopsy needle is now used under the ultrasonic guidance in almost all institutions. Kidney biopsy is considerably safer than when performed blindly, and it may be said that it is an established testing method. However, when it may be hard to obtain renal tissue, we may cancel testing on the way without overdoing it. When we cannot obtain renal tissue, or when glomeruli necessary for a diagnosis are not included, we may make a testing plan again.

There is a "laparoscopic kidney biopsy," which takes the renal tissue while confirming the kidney using laparoscopy as other methods directly (Fig. 1).

When there is the high-risk clinical condition and hemorrhagic complications by percutaneous kidney biopsy, when renal tissue is not gained by percutaneous kidney biopsy, "opening kidney biopsy" or "laparoscopic kidney biopsy" is chosen.

By light microscopy, we can observe the whole, including glomeruli, renal tubules, and the blood vessels, and can obtain basic information.

By fluorescent microscopy, we observe the presence or absence of deposition and a deposition place of immunoglobulin, including IgG, IgA, and IgM, and complements, such as C3 and C1q.

By electron microscopy, we confirm the cellular internal structure, including glomerular and tubular structure, and a deposit causing nephritis, which spreads approximately 15,000 times.

After performing three tests, a diagnosis of renal disease is made.

According to questionnaire survey by the Japanese Society of Nephrology for kidney biopsy that was performed in Japan from 2015 through 2017, out of 15,657 adult patients who underwent kidney biopsy by a nephrologist, transfusion was required in 121 cases (0.8%), hemostasis treatment by renal artery embolization in 31 cases (0.2%), gross hematuria with no treatment in 431 cases (2.8%), vesicoclysis in 56 cases (0.4%), death in one (0.006%). Close evaluation of the death cases clarified that bleeding after kidney biopsy is not a direct cause, but the overall status of these cases was poor before kidney biopsy and worsened after kidney biopsy.

Chapter 4: Pre-biopsy evaluation

Medical history

①

Detailed history of present illness.

②

Family history of renal diseases.

③

Past medical and social history.

④

History of patient medication.

Physical examination

Blood test

①

Complete blood cell count

Erythrocyte transfusion is considered for severe anemia before kidney biopsy. The cutoff value of Hb is 7–8 g/dL. Platelet transfusion is considered for severe thrombocytopenia with platelet count less than 50,000/μL.

②

Coagulation study

Tests for prothrombin time (PT), APTT, fibrinogen, and fibrin/fibrinogen degradation products (FDP) (or D-dimer) are recommended for pre-operative screening. When a coagulation abnormality is found, close examination and adequate treatment are required before kidney biopsy. When a thrombotic tendency is pointed out, especially in high-risk patients with nephrotic syndrome, screening tests for deep vein thrombosis and pulmonary embolism are also considered.

③

Biochemistry

Serum tests include total protein, albumin, urea nitrogen, creatinine, uric acid, AST, ALT, LDH, and electrolytes (Na, K, Cl, Ca, P, and Mg). Estimated GFR by using serum creatinine or cysteine C values are important to evaluate renal function. Arterial blood gas analysis (including anion gap) is also helpful for the differential diagnosis of kidney diseases with acid–base abnormality.

④

Blood sugar (glucose) test

As well as fasting plasma glucose (sugar), HbA1C and glycoalbumin are useful for evaluation of hyperglycemic conditions.

⑤

Immunology

Immunological tests include immunoglobulin (IgG, IgA, IgM, IgG4), complement (CH50, C3, C4), autoantibody (antinuclear antibody, ds-DNA, SM, RNP, ANCA, GBM, anticardiolipin, lupus anticoagulant), serum monoclonal protein.

⑥

Endocrinology

Endocrinological examinations include renin, aldosterone, and BNP.

⑦

Tests for infection

HBV, HCV, syphilis (RPR/TPHA), and HIV are screened.

Urinalysis

①

Urinary qualitative test (dipstick test).

②

Urinary sediment.

Dysmorphic erythrocytes suggest hematuria with glomerular diseases.

③

Urinary quantitative test.

Urinary protein is measured by using spot urine or 24-h collected urine. NAG, β2MG, and α1MG are useful markers for tubular dysfunction. Selectivity index (SI) is also helpful in the differential diagnosis of nephrotic proteinuria.

Imaging test

Diagnostic imaging includes US, CT, and MRI. Radioisotope examinations are also useful for understanding renal pathophysiology. 99mTc-MAG3, an isotope secreting from proximal tubules, is utilized for evaluating effective renal plasma flow (ERPF) of right and left kidneys. 99mTc-DTPA, an isotope filtrating from glomeruli, is used for the measurement of glomerular filtration rate (GFR) of right and left kidneys.

Chapter 5. Method of kidney biopsy (technique)

Setting the patient in lateral jack-knife position, through 3 cm of horizontal incision from 12 rib tip the muscles are divided in each layer to reach the inferior pole of the kidney covered by adipose tissue. Confirming not to damage the peritoneum, the circumrenal fat and Gerota fascia are cut to reach the surface of kidney. The biopsy gun for needle biopsy on the kidney or the wedge incision for block type specimen is used to take a piece of the kidney. After biopsy, hemostasis is securely performed by pressure with the forefinger for 10–15 min. The muscles and skin are closed in layers to finish the procedure. [144, 145].

Because hemostasis pressure can be provided surely as compared with a native kidney biopsy, it is not necessary to discontinue the anticoagulant therapy. However, it is desirable to conduct an examination for coagulation system in advance.
Under local anesthesia the biopsy needle is put into the kidney to take a piece of the kidney. This may be performed 2–3 times to obtain an adequate specimen.
Just after the procedure, the physician presses the puncture area for 10–15 min for hemostasis. After that A 1 kg sandbag is put on the puncture area to maintain pressure for an hour. A small pillow is fixed with elastic tape on the area. Thereafter the patient must lie in bed for 6 h or until seen by the doctor. The patient must pay attention for blood in their urine after the biopsy.
The fixing elastic tape will be removed on next morning. Before discharge a blood count, biochemistry test, and urinalysis are examined. The discharge is permitted after having confirmed that there is no hematoma and hydronephrosis around the renal graft by US [147‐149].

Chapter 6: After care of the biopsy and post procedure observation

Aftercare of the biopsy and postprocedure observation are essential to prevent hemorrhagic complications. After biopsy, bed rest for 6–8 h in an extraneous dressing room is mandated in Europe and America. In Japan, kidney biopsy is performed during hospitalization. Just after the biopsy is performed, pressure is exerted on the back by using both hands and a sandbag for hemostasis. Subsequently, bed rest in the dorsal (supine) position is common [98, 150‐160].

Chapter 7: Complications

According to the questionnaire survey results that were performed for the publication of this book, among 21,648 kidney biopsy cases that were performed in Japan, gross hematuria after kidney biopsy was found in 511 patients (2.4%), bladder wash was in 79 cases (0.36%), red blood cell transfusion was in 161 cases (0.74%), renal arterial embolization was in 44 cases (0.22%), and death occurred in one case (0.005%). The underlying cause of death in this case was not due to bleeding after kidney biopsy, but the overall status of this case was confirmed poor before kidney biopsy and worsened after kidney biopsy (Table 5) [1, 4, 5, 66, 74, 156, 169‐174].

Table 5

Bleeding complications after kidney biopsy

	Percutaneous native kidney biopsy	Percutaneous native kidney biopsy	Open biopsy	Transplanted kidney biopsy
	Adult	Children	Open biopsy	Transplanted kidney biopsy
Total number of biopsies	15,657	1685	1156	3808
Macroscopic hematuria with no treatment	431 (2.8%)	105 (6.2%)	9 (0.78%)	12 (0.31%)
Erythrocyte transfusion	121 (0.8%)	0 (0%)	4 (0.35%)	2 (0.05%)
Transcatheter arterial embolization	31 (0.2%)	1 (0.06%)	2 (0.17%)	4 (0.1%)
Bladder lavage	56 (0.4%)	9 (0.5%)	0 (0%)	0 (0%)
Nephrectomy	0 (0%)	0 (0%)	0	1 (0.03%)

Results from questionnaire survey for kidney biopsy that was performed in Japan from 2015 through 2017

Chapter 8: Histological evaluation of kidney biopsy specimen

Kidney biopsy remains the gold standard to diagnose renal disease and evaluate acute and chronic renal damages. Specimens are processed for the diagnostic approach of light microscopy (LM), immunostaining by immunofluorescence (IF) or immunohistochemistry, and electron microscopy (EM). To minimize the bleeding risk, less passes to obtain tissue is desirable; on the other hand, sufficient quantity of tissue is required for definite diagnosis. When small sample size of renal tissues was obtained, dividing samples appropriately into LM, IF, and EM studies should be carefully considered (Fig. 2).

Chapter 9: Kidney biopsy in children

Kidney biopsy in the pediatric population was reported for the first time in 1958 and has a history of more than 60 years [204]. The procedure has become relatively safe in children as well as in adults owing to technical advances and improvement of medical devices. However, the indication for kidney biopsy must be carefully determined based on benefits and potential risks for serious bleeding complications.

Indication of kidney biopsy (Table 6)

Table 6

Indication of kidney biopsy in children

1. Abnormal urinalysis	1. Isolated proteinuria 0.5 g/gCr or more
	2. Proteinuria and glomerular hematuria
2. Nephrotic syndrome	1. Steroid-resistant nephrotic syndrome
	2. Coexistence of hematuria, hypertension, renal dysfunction, and hypocomplementemia
	3. Congenital nephrotic syndrome
3. Systemic disease with a urinalysis abnormality	1. Systemic lupus erythematosus
	2. IgA vasculitis (Purpura nephritis)
	3. Microscopic polyangiitis
	4. Others
4. Intrinsic acute kidney injury
5. Others	1. Drug-related disease
	2. Transplanted kidney

Kidney biopsy for clinical condition with high risk

Kidney biopsy is indicated according to adult criteria [214].

Pre-biopsy evaluation

We may need sedation or general anesthesia in children. Therefore, it is necessary to evaluate the airway and the overall status (underlying disease) beforehand.

Method of kidney biopsy (technique)

Sedation

Ketamine (Ketalar) (initial dose, 1–2 mg/kg): duration of action is 5–10 min.

Midazolam (Dormicum) (initial dose, 0.05–0.1 mg/kg): half-life in blood is 0.8–1.8 h.

Pentazocine (Sosegon) (initial dose, 0.5–1.5 mg/kg): half-life in blood is 3–4 h

Thiopental (Ravonal), Thiamylal (Isozol) (initial dose, 4–6 mg/kg): duration of action is ten minutes.

Propofol (Diprivan) (initial dose, infants 3–5 mg/kg, older children 2.5–3 mg/kg): duration of action is 5–15 min.

After care of the biopsy and post procedure observation

Complications

Chapter 10: Biopsy of transplanted kidney

For the long-term engraftment after the renal transplant, early detection and early treatment for rejection or early detection of the side effect with the immunosuppressive drug are important. Because treatment totally varies according to clinical condition, the pathological evaluation of the renal graft tissue is important in treatment strategy decision. These clinical conditions occur asymptomatically and may progress.

Episode biopsy: Transplant kidney biopsy is generally performed when an acute renal allograft rejection is suspected within a year after operation. The main clinical indicator is an increase in serum creatinine levels of 20% above a baseline value. Furthermore, a year after operation, for patients with renal dysfunction or proteinuria, the following diseases are clarified by kidney biopsy; chronic allograft nephropathy (CAN), chronic rejection (antibody-mediated rejection and T cell-mediated rejection), recurrence of underlying disease and calcineurin inhibitors nephrotoxicity [76, 149, 249].

Protocol biopsy: kidney biopsy is performed at the renal transplant surgery for 0 h (just after perfusion of the isolated kidney), an hour (after renal graft blood flow resumption), at post transplantation 2–3 months, and at a year after. Whether immunosuppressive therapy is appropriate, asymptomatic acute rejection occurs, or underlying disease recurs can be determined.

Chapter 11: Open (surgical) kidney biopsy and laparoscopic kidney biopsy

Surgeons directly look at the surface of the kidneys and determine the area from which the tissue samples should be taken. There are two type of methods including a needle biopsy and wedge biopsy. The incidence of severe bleeding of renal surface is very low, and mortality is rare, but the risk of hemorrhage into the urinary tract exists. Attention is necessary for the development of renal arteriovenous fistula (arteriovenous fistula: AVF) causing bleeding to the urinary tract. Other relatively minor postoperative complications including fever, atelectasis, and ileus can occur. In addition, an open biopsy under general anesthesia is associated with a longer hospital stay and a larger surgical scar. On wedge biopsy, the specimens may increase the proportion of shallow layer of the cortex resulting in less information of the cortex deep part and medulla [4].

As for the complications peculiar to laparoscopic kidney biopsy, nephric subcapsular hematoma, subcutaneous emphysema, peritoneal injury, and injury of the circumference organ are reported.
An advantage of laparoscopic kidney biopsy in comparison with the percutaneous kidney biopsy includes certain sampling of renal tissue as well as confirmation and hemostasis of a bleeding point.
An advantage of laparoscopic kidney biopsy in comparison to open kidney biopsy includes shortening of the hospital stay, pain reduction, and compatibility of the incised wound [4].

Acknowledgements

The study was supported by the Japanese Society of Nephrology. The authors would like to thank Naoki Kashihara (President of the Japanese Society of Nephrology), and the members of the Japanese Society of Nephrology.

Compliance with ethical standards

Conflict of interest

No authors have declared any competing interest about the contribution of this article. All the authors have declared no conflict of interest exists.

Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Unsere Produktempfehlungen

e.Med Interdisziplinär

Kombi-Abonnement

Für Ihren Erfolg in Klinik und Praxis - Die beste Hilfe in Ihrem Arbeitsalltag

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Fachzeitschriften auf SpringerMedizin.de.

Jetzt testen ¹

e.Med Allgemeinmedizin

Kombi-Abonnement

Mit e.Med Allgemeinmedizin erhalten Sie Zugang zu allen CME-Fortbildungen und Premium-Inhalten der allgemeinmedizinischen Zeitschriften, inklusive einer gedruckten Allgemeinmedizin-Zeitschrift Ihrer Wahl.

Jetzt testen ²

e.Med Innere Medizin

Kombi-Abonnement

Mit e.Med Innere Medizin erhalten Sie Zugang zu CME-Fortbildungen des Fachgebietes Innere Medizin, den Premium-Inhalten der internistischen Fachzeitschriften, inklusive einer gedruckten internistischen Zeitschrift Ihrer Wahl.

Jetzt testen ³

e.Med Urologie

Kombi-Abonnement

Mit e.Med Urologie erhalten Sie Zugang zu den urologischen CME-Fortbildungen und Premium-Inhalten der urologischen Fachzeitschriften.

Jetzt testen ⁴

Japanese Society of Nephrology. Guidebook of the kidney biopsy. Tokyo: Tokyo-Igakusha; 2004. (In Japanese).

Salama AD, Cook HT. The kidney biopsy. In: Skorecki K, Chertow GM, Marsden PA, Taal MW, Yu AS, editors. Brenner & Rector’s The Kidney. 10th ed. New York: Elsevier; 2016.

Dhaun N, Bellamy CO, Cattran DC, Kluth DC. Utility of kidney biopsy in the clinical management of renal disease. Kidney Int. 2014;85:1039–48.PubMedCrossRef

Kawaguchi T, Nagasawsa T, Tsuruya K, Miura K, Katsuno T, Morikawa T, Ishikawa E, Ogura M, Matsumura H, Kurayama R, Matsumoto S, Marui Y, Hara S, Maruyama S, Narita I, Okada H, Ubara Y, Committee of Practical Guide for Kidney Biopsy 2019. Correction to: A nationwide survey on clinical practice patterns and bleeding complications of percutaneous native kidney biopsy in Japan. Clin Exp Nephrol. 2020a;24(5):389–401.PubMedPubMedCentralCrossRef

Kawaguchi T, Nagasawsa T, Tsuruya K, Miura K, Katsuno T, Morikawa T, Ishikawa E, Ogura M, Matsumura H, Kurayama R, Matsumoto S, Marui Y, Hara S, Maruyama S, Narita I, Okada H, Ubara Y, Committee of Practical Guide for Kidney Biopsy 2019. A nationwide survey on clinical practice patterns and bleeding complications of percutaneous native kidney biopsy in Japan. Clin Exp Nephrol. 2020b;24(5):402–3.PubMedPubMedCentralCrossRef

Yamagata K, Takahashi H, Tomida C, Yamagata Y, Koyama A. Prognosis of asymptomatic hematuria and/or proteinuria in men. High prevalence of IgA nephropathy among proteinuric patients found in mass screening. Nephron. 2002;91:34–42.PubMedCrossRef

Kawamura T, Ohta T, Ohno Y, Wakai K, Aoki R, Tamakoshi A, Maeda K, Mizuno Y. Significance of urinalysis for subsequent kidney and urinary tract disorders in mass screening of adults. Intern Med. 1995;34:475–80.PubMedCrossRef

Nieuwhof C, Doorenbos C, Grave W, de Heer F, de Leeuw P, Zeppenfeldt E, van Breda Vriesman PJ. A prospective study of the natural history of idiopathic non-proteinuric hematuria. Kidney Int. 1996;49:222–5.PubMedCrossRef

Vivante A, Afek A, Frenkel-Nir Y, Tzur D, Farfel A, Golan E, Chaiter Y, Shohat T, Skorecki K, Calderon-Margalit R. Persistent asymptomatic isolated microscopic hematuria in Israeli adolescents and young adults and risk for end-stage renal disease. JAMA. 2011;306:729–36.PubMedCrossRef

10.

Richards NT, Darby S, Howie AJ, Adu D, Michael J. Knowledge of renal histology alters patient management in over 40% of cases. Nephrol Dial Transplant. 1994;9:1255–9.PubMed

11.

Iseki K, Ikemiya Y, Iseki C, Takishita S. Proteinuria and the risk of developing end-stage renal disease. Kidney Int. 2003a;63:1468–74.PubMedCrossRef

12.

Iseki K, Ikemiya Y, Iseki C, Takishita S. The okinawa screening program. J Am Soc Nephrol. 2003b;14(7 Suppl 2):S127-130.PubMedCrossRef

13.

Berden AE, Ferrario F, Hagen EC, Jayne DR, Jennette JC, Joh K, Neumann I, Noël LH, Pusey CD, Waldherr R, Bruijn JA, Bajema IM. Histopathologic classification of ANCA-associated glomerulonephritis. J Am Soc Nephrol. 2010;21:1628–36.PubMedCrossRef

14.

Muso E, Endo T, Itabashi M, Kakita H, Iwasaki Y, Tateishi Y, Komiya T, Ihara T, Yumura W, Sugiyama T, Joh K, Suzuki K. Evaluation of the newly proposed simplified histological classification in Japanese cohorts of myelo-peroxidase-anti-neutrophil cytoplasmic antibody-associated glomerulonephritis in comparison with other Asian and European cohorts. Clin Exp Nephrol. 2013;17:659–62.PubMedCrossRef

15.

Berden AE, Jones RB, Erasmus DD, Walsh M, Noël LH, Ferrario F, Waldherr R, Bruijn JA, Jayne DR, Bajema IM, European Vasculitis Society. Tubular lesions predict renal outcome in antineutrophil cytoplasmic antibody-associated glomerulo-nephritis after rituximab therapy. J Am Soc Nephrol. 2012;23:313–21.PubMedCrossRef

16.

Merkel F, Pullig O, Marx M, Netzer KO, Weber M. Course and prognosis of anti-basement membrane antibody (anti-BM-Ab)-mediated disease: report of 35 cases. Nephrol Dial Transplant. 1994;9:372–6.PubMed

17.

Levy JB, Turner AN, Rees AJ, Pusey CD. Long-term outcome of anti-glomerular basement membrane antibody disease treated with plasma exchange and immunosuppression. Ann Intern Med. 2001;134:1033–42.PubMedCrossRef

18.

Alchi B, Griffiths M, Sivalingam M, Jayne D, Farrington K. Predictors of renal and patient outcomes in anti-GBM disease: clinicopathologic analysis of a two-centre cohort. Nephrol Dial Transplant. 2015;30:814–21.PubMedCrossRef

19.

Kellum JA, Lameire N, KDIGO AKI Guideline Work Group. Diagnosis, evaluation, and management of acute kidney injury: a KDIGO summary (Part 1). Crit Care. 2013;17:204.PubMedPubMedCentralCrossRef

20.

Palevsky PM, Zhang JH, O’Connor TZ, Chertow GM, Crowley ST, Choudhury D, Finkel K, Kellum JA, Paganini E, Schein RM, Smith MW, Swanson KM, Thompson BT, Vijayan A, Watnick S, Star RA, Peduzzi P. Intensity of renal support in critically ill patients with acute kidney injury". N Engl J Med. 2008;359:7–20.PubMedCrossRef

21.

Weening JJ, D’Agati VD, Schwartz MM, Seshan SV, Alpers CE, Appel GB, Balow JE, Bruijn JA, Cook T, Ferrario F, Fogo AB, Ginzler EM, Hebert L, Hill G, Hill P, Jennette JC, Kong NC, Lesavre P, Lockshin M, Looi LM, Makino H, Moura LA, Nagata M, International Society of Nephrology Working Group on the Classification of Lupus Nephritis. The classification of glomerulonephritis in systemic lupus erythematosus revisited. J Am Soc Nephrol. 2004;15:241–50.PubMedCrossRef

22.

Parikh SV, Rovin BH. Current and emerging therapies for lupus nephritis. J Am Soc Nephrol. 2016;27:2929–39.PubMedPubMedCentralCrossRef

23.

Almaani S, Meara A, Rovin BH. Update on lupus nephritis. Clin J Am Soc Nephrol. 2017;12:825–35.PubMedCrossRef

24.

Toriu N, Sawa N, Oguro M, Mizuno H, Oshima Y, Hasegawa E, Sumida K, Suwabe T, Kawada M, Ueno T, Hayami N, Sekine A, Hiramatsu R, Yamanouchi M, Hoshino J, Takaichi K, Ohashi K, Fujii T, Yanagita M, Ubara Y. Renal-limited cryoglobulinemic vasculitis: two case reports. Intern Med. 2018;57(13):1879–86.PubMedPubMedCentralCrossRef

25.

Endo A, Hoshino J, Suwabe T, Sumida K, Mise K, Hiramatsu R, Hasegawa E, Yamanouchi M, Hayami N, Sawa N, Takaichi K, Ohashi K, Fujii T, Ubara Y. Significance of small renal artery lesions in patients with antineutrophil cytoplasmic antibody-associated glomerulonephritis. J Rheumatol. 2014;41(6):1140–6.PubMedCrossRef

26.

Mahajan SK, Ordóñez NG, Feitelson PJ, Lim VS, Spargo BH, Katz AI. Lupus nephropathy without clinical renal involvement. Medicine (Baltimore). 1977;56:493–501.CrossRef

27.

Wada Y, Ito S, Ueno M, Nakano M, Arakawa M, Gejyo F. Renal outcome and predictors of clinical renal involvement in patients with silent lupus nephritis. Nephron Clin Pract. 2004;98:c105-111.PubMedCrossRef

28.

Wakasugi D, Gono T, Kawaguchi Y, Hara M, Koseki Y, Katsumata Y, Hanaoka M, Yamanaka H. Frequency of class III and IV nephritis in systemic lupus erythematosus without clinical renal involvement: an analysis of predictive measures. J Rheumatol. 2012;39:79–85.PubMedCrossRef

29.

Hasegawa J, Hoshino J, Sekine A, Hayami N, Suwabe T, Sumida K, Mise K, Ueno T, Yamanouchi M, Hazue R, Sawa N, Ohashi K, Fujii T, Takaichi K, Ubara Y. Clinical and pathological features of anti-neutrophil cytoplasmic antibody-associated vasculitis in patients with minor urinary abnormalities. Nephrology (Carlton). 2018;23:1007–12.CrossRef

30.

Hoshino J, Furuichi K, Yamanouchi M, Mise K, Sekine A, Kawada M, Sumida K, Hiramatsu R, Hasegawa E, Hayami N, Suwabe T, Sawa N, Hara S, Fujii T, Ohashi K, Kitagawa K, Toyama T, Shimizu M, Takaichi K, Ubara Y, Wada T. A new pathological scoring system by the Japanese classification to predict renal outcome in diabetic nephropathy. PLoS ONE. 2018;13:e0190923.PubMedPubMedCentralCrossRef

31.

Toriu N, Yamanouchi M, Hiramatsu R, Hayami N, Hoshino J, Sekine A, Kawada M, Hasegawa E, Suwabe T, Sumida K, Ueno T, Sawa N, Ohashi K, Fujii T, Takaichi K, Yanagita M, Kobayasi T, Ubara Y. Preservation of renal function by intensive glycemic control. Endocrinol Diabetes Metab Case Rep. 2018;2018:17–0136.PubMedPubMedCentral

32.

Yamanouchi M, Hoshino J, Ubara Y, Takaichi K, Kinowaki K, Fujii T, Ohashi K, Mise K, Toyama T, Hara A, Kitagawa K, Shimizu M, Furuichi K, Wada T. Value of adding the renal pathological score to the kidney failure risk equation in advanced diabetic nephropathy. PLoS ONE. 2018;13:e0190930.PubMedPubMedCentralCrossRef

33.

Furuichi K, Shimizu M, Yuzawa Y, Hara A, Toyama T, Kitamura H, Suzuki Y, Sato H, Uesugi N, Ubara Y, Hohino J, Hisano S, Ueda Y, Nishi S, Yokoyama H, Nishino T, Kohagura K, Ogawa D, Mise K, Shibagaki Y, Makino H, Matsuo S, Wada T, Research Group of Diabetic Nephropathy, Ministry of Health, Labour and Welfare of Japan, and Japan Agency for Medical Research and Development. Clinicopathological analysis of biopsy-proven diabetic nephropathy based on the Japanese classification of diabetic nephropathy. Clin Exp Nephrol. 2018;22:570–82.PubMedCrossRef

34.

Mise K, Ueno T, Hoshino J, Hazue R, Sumida K, Yamanouchi M, Hayami N, Suwabe T, Hiramatsu R, Hasegawa E, Sawa N, Fujii T, Hara S, Wada J, Makino H, Takaichi K, Ohashi K, Ubara Y. Nodular lesions in diabetic nephropathy: collagen staining and renal prognosis. Diabetes Res Clin Pract. 2017;127:187–97.PubMedCrossRef

35.

Furuichi K, Yuzawa Y, Shimizu M, Hara A, Toyama T, Kitamura H, Suzuki Y, Sato H, Uesugi N, Ubara Y, Hisano S, Ueda Y, Nishi S, Yokoyama H, Nishino T, Kohagura K, Ogawa D, Mise K, Shibagaki Y, Kimura K, Haneda M, Makino H, Matsuo S, Wada T. Nationwide multicentre kidney biopsy study of Japanese patients with type 2 diabetes. Nephrol Dial Transplant. 2018;33:138–48.PubMedCrossRef

36.

Hoshino J, Mise K, Ueno T, Imafuku A, Kawada M, Sumida K, Hiramatsu R, Hasegawa E, Yamanouchi M, Hayami N, Suwabe T, Sawa N, Hara S, Fujii T, Ohashi K, Ubara Y, Takaichi K. A pathological scoring system to predict renal outcome in diabetic nephropathy. Am J Nephrol. 2015;41:337–44.PubMedCrossRef

37.

Mise K, Hoshino J, Ueno T, Sumida K, Hiramatsu R, Hasegawa E, Yamanouchi M, Hayami N, Suwabe T, Sawa N, Fujii T, Hara S, Ohashi K, Takaichi K, Ubara Y. Clinical implications of linear immunofluorescent staining for immunoglobulin G in patients with diabetic nephropathy. Diabetes Res Clin Pract. 2014;106:522–30.PubMedCrossRef

38.

Mise K, Hoshino J, Ubara Y, Sumida K, Hiramatsu R, Hasegawa E, Yamanouchi M, Hayami N, Suwabe T, Sawa N, Fujii T, Ohashi K, Hara S, Takaichi K. Renal prognosis a long time after kidney biopsy on patients with diabetic nephropathy. Nephrol Dial Transplant. 2014;29:109–18.PubMedCrossRef

39.

Mise K, Yamaguchi Y, Hoshino J, Ueno T, Sekine A, Sumida K, Yamanouchi M, Hayami N, Suwabe T, Hiramatsu R, Hasegawa E, Sawa N, Fujii T, Hara S, Sugiyama H, Makino H, Wada J, Ohashi K, Takaichi K, Ubara Y. Paratubular basement membrane insudative lesions predict renal prognosis in patients with type 2 diabetes and biopsy-proven diabetic nephropathy. PLoS ONE. 2017;12:e0183190.PubMedPubMedCentralCrossRef

40.

Mise K, Hoshino J, Ueno T, Hazue R, Hasegawa J, Sekine A, Sumida K, Hiramatsu R, Hasegawa E, Yamanouchi M, Hayami N, Suwabe T, Sawa N, Fujii T, Hara S, Ohashi K, Takaichi K, Ubara Y. Prognostic value of tubulointerstitial lesions, urinary N-acetyl-β-d-glucosaminidase, and urinary β2-microglobulin in patients with type 2 diabetes and biopsy-proven diabetic nephropathy. Clin J Am Soc Nephrol. 2016;11:593–601.PubMedPubMedCentralCrossRef

41.

Mise K, Hoshino J, Ueno T, Imafuku A, Kawada M, Sumida K, Hiramatsu R, Hasegawa E, Yamanouchi M, Hayami N, Suwabe T, Sawa N, Fujii T, Hara S, Ohashi K, Takaichi K, Ubara Y. Impact of tubulointerstitial lesions on anaemia in patients with biopsy-proven diabetic nephropathy. Diabet Med. 2015;32:546–55.PubMedCrossRef

42.

Moriya T, Omura K, Matsubara M, Yoshida Y, Hayama K, Ouchi M. Arteriolar hyalinosis predicts increase in albuminuria and GFR Decline in Normo- and micro-albuminuric japanese patients with type 2 diabetes. Diabetes Care. 2017;40:1373–8.PubMedCrossRef

43.

Mazzucco G, Bertani T, Fortunato M, Bernardi M, Leutner M, Boldorini R, Monga G. Different patterns of renal damage in type 2 diabetes mellitus: a multicentric study on 393 biopsies. Am J Kidney Dis. 2002;39:713–20.PubMedCrossRef

44.

Sharma SG, Bomback AS, Radhakrishnan J, Herlitz LC, Stokes MB, Markowitz GS, D’Agati VD. The modern spectrum of kidney biopsy findings in patients with diabetes. Clin J Am Soc Nephrol. 2013;8:1718–24.PubMedPubMedCentralCrossRef

45.

Nair R, Bell JM, Walker PD. Kidney biopsy in patients aged 80 years and older. Am J Kidney Dis. 2004;44:618–26.PubMedCrossRef

46.

Omokawa A, Komatsuda A, Nara M, Fujiwara T, Sato R, Togashi M, Okuyama S, Sawada K, Wakui H. Kidney biopsy in patients aged 80 years and older: a single-center experience in Japan. Clin Nephrol. 2012;77:461–7.PubMedCrossRef

47.

Moutzouris DA, Herlitz L, Appel GB, Markowitz GS, Freudenthal B, Radhakrishnan J, D’Agati VD. Kidney biopsy in the very elderly. Clin J Am Soc Nephrol. 2009;4:1073–82.PubMedPubMedCentralCrossRef

48.

Bomback AS, Appel GB, Radhakrishnan J, Shirazian S, Herlitz LC, Stokes B, D’Agati VD, Markowitz GS. ANCA-associated glomerulonephritis in the very elderly. Kidney Int. 2011;79:757–64.PubMedCrossRef

49.

Savige J, Gregory M, Gross O, Kashtan C, Ding J, Flinter F. Expert guidelines for the management of Alport syndrome and thin basement membrane nephropathy. J Am Soc Nephrol. 2013;24(3):364–75.PubMedCrossRef

50.

Imafuku A, Nozu K, Sawa N, Hasegawa E, Hiramatsu R, Kawada M, Hoshino J, Tanaka K, Ishii Y, Takaichi K, Fujii T, Ohashi K, Iijima K, Ubara Y. Autosomal dominant form of type IV collagen nephropathy exists among patients with hereditary nephritis difficult to diagnose clinicopathologically. Nephrology (Carlton). 2018;23:940–7.CrossRef

51.

Imafuku A, Nozu K, Sawa N, Nakanishi K, Ubara Y. How to resolve confusion in the clinical setting for the diagnosis of heterozygous COL4A3 or COL4A4 gene variants? Discussion and suggestions from nephrologists. Clin Exp Nephrol. 2020;24:651–6.PubMedPubMedCentralCrossRef

52.

Nachman PH. Repeat kidney biopsy for lupus nephritis: an important step forward. Kidney Int. 2018;94:659–61.PubMedCrossRef

53.

De Rosa M, Azzato F, Toblli JE, De Rosa G, Fuentes F, Nagaraja HN, Nash R, Rovin BH. A prospective observational cohort study highlights kidney biopsy findings of lupus nephritis patients in remission who flare following withdrawal of maintenance therapy. Kidney Int. 2018;94:788–94.PubMedCrossRef

54.

Pakozdi A, Pyne D, Sheaff M, Rajakariar R. Utility of a repeat kidney biopsy in lupus nephritis: a single centre experience. Nephrol Dial Transplant. 2018;33:507–13.PubMedCrossRef

55.

Hruskova Z, Honsova E, Berden AE, Rychlik I, Lanska V, Zabka J, Bajema IM, Tesar V. Repeat protocol kidney biopsy in ANCA-associated renal vasculitis. Nephrol Dial Transplant. 2014;29:1728–32.PubMedCrossRef

56.

Shima Y, Nakanishi K, Kamei K, Togawa H, Nozu K, Tanaka R, Sasaki S, Iijima K, Yoshikawa N. Disappearance of glomerular IgA deposits in childhood IgA nephropathy showing diffuse mesangial proliferation after 2 years of combination/prednisolone therapy. Nephrol Dial Transplant. 2011;26:163–9.PubMedCrossRef

57.

Shen XH, Liang SS, Chen HM, Le WB, Jiang S, Zeng CH, Zhou ML, Zhang HT, Liu ZH. Reversal of active glomerular lesions after immunosuppressive therapy in patients with IgA nephropathy: a repeat-biopsy based observation. J Nephrol. 2015;28:441–9.PubMedCrossRef

58.

Ahmad H, Tejani A. Predictive value of repeat renal biopsies in children with nephrotic syndrome. Nephron. 2000;84:342–6.PubMedCrossRef

59.

Zhong Y, Xu F, Li X, Chen H, Liang S, Zhu X, Liu Z, Zeng C. The evolution of morphological variants of focal segmental glomerulosclerosis: a repeat biopsy-based observation. Nephrol Dial Transplant. 2016;31:87–95.PubMedCrossRef

60.

Ubara Y, Hara S, Katori H, Tagami T, Kitamura A, Yokota M, Matsushita Y, Takemoto F, Yamada A, Nagahama K, Hara M, Chayama K. Splenectomy may improve the glomerulopathy of type II mixed cryoglobulinemia. Am J Kidney Dis. 2000;35:1186–92.PubMedCrossRef

61.

Iwadate D, Hasegawa E, Hoshino J, Hayami N, Sumida K, Yamanouchi M, Sekine A, Kawada M, Hiramatsu R, Suwabe T, Sawa N, Yuasa M, Wake A, Fujii T, Ohashi K, Takaichi K, Ubara Y. The long-term outcomes after VAD plus SCT therapy in a patient with AL amyloidosis and severe factor X deficiency. Intern Med. 2018;57:701–6.PubMedCrossRef

62.

Ueno T, Kikuchi K, Hazue R, Mise K, Sumida K, Hayami N, Suwabe T, Hoshino J, Sawa N, Arizono K, Hara S, Takaichi K, Fujii T, Ohashi K, Ubara Y. Five sequential evaluations of renal histology in a patient with light chain deposition disease. Intern Med. 2016;55:2993–9.PubMedPubMedCentralCrossRef

63.

Toriu N, Sawa N, Hiramatsu R, Mizuno H, Ikuma D, Sekine A, Hayami N, Sumida K, Yamanouchi M, Hasegawa E, Hoshino J, Takaichi K, Wake A, Ohashi K, Fujii T, Ubara Y. Regression of renal amyloid deposits by VAD therapy plus autologous stem cell transplantation in a patient with primary AL amyloidosis. CEN Case Rep. 2020;9(1):6–10.PubMedCrossRef

64.

Health and Public Policy Committee. American College of Physicians. Clinical competence in percutaneous kidney biopsy. Ann Intern Med. 1988;108:301–3.CrossRef

65.

Doyle AJ, Gregory MC, Terreros DA. Percutaneous native kidney biopsy: comparison of a 1.2-mm spring-driven system with a traditional 2-mm hand-driven system. Am J Kidney Dis. 1994;23:498–503.PubMedCrossRef

66.

Hogan JJ, Mocanu M, Berns JS. The native kidney biopsy: update and evidence for best practice. Clin J Am Soc Nephrol. 2016;11:354–62.PubMedCrossRef

67.

Fine DM, Arepally A, Hofmann LV, Mankowitz SG, Atta MG. Diagnostic utility and safety of transjugular kidney biopsy in the obese patient. Nephrol Dial Transplant. 2004;19:1798–802.PubMedCrossRef

68.

Margaryan A, Perazella MA, Mahnensmith RL, Abu-Alfa AK. Experience with outpatient computed tomographic-guided kidney biopsy. Clin Nephrol. 2010;74:440–5.PubMedCrossRef

69.

Mukhtar KN, Mahmood SN, Umair SF. CT guided percutaneous kidney biopsy versus ultrasound guided for obtaining adequate tissue. J Pak Med Assoc. 2012;62:880–2.PubMed

70.

McDougal WS, Tolkoff-Rubin NE, Michaelson MD, Mueller PR, Braaten K. Case records of the Massachusetts General Hospital. Case 28-2006. A 59-year-old man with masses in both kidneys. N Engl J Med. 2006;355:1161–7.PubMedCrossRef

71.

Mizunoe S, Yamasaki T, Tokimatsu I, Kushima H, Matsunaga N, Hashinaga K, Miyazaki Y, Komatsu E, Kadota J. Sarcoidosis associated with renal masses on computed tomography. Intern Med. 2006;45:279–82.PubMedCrossRef

72.

Ubara Y, Hara S, Katori H, Yamada A, Morii H. Renovascular hypertension may cause nephrotic range proteinuria and focal glomerulosclerosis in contralateral kidney. Clin Nephrol. 1997;48:220–3.PubMed

73.

Bandari J, Fuller TW, Turner Ii RM, D’Agostino LA. kidney biopsy for medical renal disease: indications and contraindications. Can J Urol. 2016a;23:8121–6.PubMed

74.

Corapi KM, Chen JL, Balk EM, Gordon CE. Bleeding complications of native kidney biopsy: a systematic review and meta-analysis. Am J Kidney Dis. 2012;60:62–73.PubMedCrossRef

75.

Schow DA, Vinson RK, Morrisseau PM. Percutaneous kidney biopsy of the solitary kidney: a contraindication? J Urol. 1992;147:1235–7.PubMedCrossRef

76.

Wilczek HE. Percutaneous needle biopsy of the renal allograft. A clinical safety evaluation of 1129 biopsies. Transplantation. 1990;50:790–7.PubMedCrossRef

77.

Tøndel C, Vikse BE, Bostad L, Svarstad E. Safety and complications of percutaneous kidney biopsies in 715 children and 8573 adults in Norway 1988–2010. Clin J Am Soc Nephrol. 2012;7:1591–7.PubMedPubMedCentralCrossRef

78.

Mejía-Vilet JM, Márquez-Martínez MA, Cordova-Sanchez BM, Ibargüengoitia MC, Correa-Rotter R, Morales-Buenrostro LE. Simple risk score for prediction of haemorrhagic complications after a percutaneous kidney biopsy. Nephrology (Carlton). 2018a;23:523–9.CrossRef

79.

Sumida K, Ubara Y, Marui Y, Nakamura M, Takaichi K, Tomikawa S, Fujii T, Ohashi K. Recurrent proliferative glomerulonephritis with monoclonal IgG deposits of IgG2λ subtype in a trans-planted kidney: a case report. Am J Kidney Dis. 2013;62:587–90.PubMedCrossRef

80.

Matsunami M, Ubara Y, Sumida K, Oshima Y, Oguro M, Kinoshita K, Tanaka K, Nakamura Y, Kinowaki K, Ohashi K, Fujii T, Igawa T, Sato Y, Ishii Y. The efficacy and safety of anti-interleukin-6 receptor monoclonal blockade in a renal transplant patient with Castleman disease: early post-transplant outcome. BMC Nephrol. 2018;19(1):263.PubMedPubMedCentralCrossRef

81.

Glenn JF. Analysis of 51 patients with horseshoe kidney. N Engl J Med. 1959;261:684–7.PubMedCrossRef

82.

Satav V, Sabale V, Pramanik P, Kanklia SP, Mhaske S. Percutaneous nephrolithotomy of horseshoe kidney: our institutional experience. Urol Ann. 2018;10:258–62.PubMedPubMedCentralCrossRef

83.

Glodny B, Petersen J, Hofmann KJ, Schenk C, Herwig R, Trieb T, Koppelstaetter C, Steingruber I, Rehder P. Kidney fusion anomalies revisited: clinical and radiological analysis of 209 cases of crossed fused ectopia and horseshoe kidney. BJU Int. 2009;103:224–35.PubMedCrossRef

84.

Hu P, Jin M, Xie Y, Chen P, Zhang X, Yin Z, Cai G, Chen X. Immunoglobulin A nephropathy in horseshoe kidney: case reports and literature review. Nephrology (Carlton). 2014;19:605–9.CrossRef

85.

Chaabouni Y, Guesmi R, Hentati Y, Kammoun K, Hmida MB, Mnif Z, Boudawara T, Hachicha J. Minimal change disease in horseshoe kidney. Pan Afr Med J. 2017;26:243.PubMedPubMedCentralCrossRef

86.

Sumida K, Ubara Y, Hoshino J, Hayami N, Suwabe T, Hiramatsu R, Hasegawa E, Yamanouchi M, Sawa N, Takaichi K, Ohashi K. Myeloperoxidase-antineutrophil cytoplasmic antibody-associated crescentic glomerulonephritis in autosomal dominant polycystic kidney disease. BMC Nephrol. 2013;14:94.PubMedPubMedCentralCrossRef

87.

Ito Y, Sekine A, Takada D, Yabuuchi J, Kogure Y, Ueno T, Sumida K, Yamanouchi M, Hayami N, Suwabe T, Hoshino J, Sawa N, Takaichi K, Kinowaki K, Fujii T, Ohashi K, Kikuchi H, Mandai S, Chiga M, Mori T, Sohara E, Uchida S, Ubara Y. Renal histology and MRI findings in a 37-year-old Japanese patient with autosomal recessive polycystic kidney disease. Clin Nephrol. 2017;88:292–7.PubMedCrossRef

88.

Takada D, Sekine A, Yabuuchi J, Kogure Y, Ueno T, Yamanouchi M, Sumida K, Suwabe T, Hayami N, Hoshino J, Takaichi K, Kinowaki K, Fujii T, Ohashi K, Mori T, Sohara E, Uchida S, Ubara Y. Renal histology and MRI in a 25-year-old Japanese man with nephronophthisis 4. Clin Nephrol. 2018;89:223–8.PubMedCrossRef

89.

Hirabayashi Y, Ishikawa E, Ito M. Bilateral renal hilar tumors in IgG4-related disease. Clin Exp Nephrol. 2017;21:1131–2.PubMedCrossRef

90.

Senekjian HO, Stinebaugh BJ, Mattioli CA, Suki WN. Irreversible renal failure following vesicoureteral reflux. JAMA. 1979;241:160–2.PubMedCrossRef

91.

Imai T, Yumura W, Takemoto F, Kotoda A, Imai R, Inoue M, Hironaka M, Muto S, Kusano E. A case of IgG4-related tubulointerstitial nephritis with left hydronephrosis after a remission of urinary tract tuberculosis. Rheumatol Int. 2013;33:2141–4.PubMedCrossRef

92.

Obayashi M, Uzu T, Harada T, Yamato M, Takahara K, Yamauchi A. Two cases of lupus cystitis complicated by lupus nephritis treated successfully with steroid therapy. Nihon Jinzo Gakkai Shi. 2003;45:765–70 (In Japanese).PubMed

93.

Takeuchi Y, Takeuchi E, Kamata K. A possible clue for the production of anti-glomerular basement membrane antibody associated with ureteral obstruction and hydronephrosis. Case Rep Nephrol Dial. 2015;5:87–95.PubMedPubMedCentralCrossRef

94.

Shibata S, Ubara Y, Sawa N, Tagami T, Hosino J, Yokota M, Katori H, Takemoto F, Hara S, Takaichi K, Fujii A, Murata H, Nishi T. Severe interstitial cystitis associated with Sjögren’s syndrome. Intern Med. 2004;43(3):248–52.PubMedCrossRef

95.

Nonaka K, Ubara Y, Sumida K, Hiramatsu R, Hasegawa E, Yamanouchi M, Hayami N, Suwabe T, Hoshino J, Sawa N, Takaichi K, Kuroda Y, Oohashi K. Clinical and pathological evaluation of hypertensive emergency-related nephropathy. Intern Med. 2013;52:45–53.PubMedCrossRef

96.

Takada D, Hoshino J, Kikuchi K, Yabuuchi J, Kogure Y, Ueno T, Sekine A, Yamanouchi M, Sumida K, Mise K, Suwabe T, Hayami N, Sawa N, Takaichi K, Hayasi N, Fujii T, Ohashi K, Ubara Y. Anti-RNA polymerase III antibody-associated scleroderma renal crisis in a patient with limited cutaneous systemic sclerosis: a case report. Mod Rheumatol. 2018;28:369–72.PubMedCrossRef

97.

Yamanouchi M, Ubara Y, Imafuku A, Kawada M, Koki M, Sumida K, Hiramatsu R, Hasegawa E, Hayami N, Suwabe T, Hoshino J, Sawa N, Ohashi K, Fujii T, Matsuda M, Takaichi K. Malignant nephrosclerosis in a patient with familial Mediterranean fever. Intern Med. 2015;54:2643–6.PubMedCrossRef

98.

Shidham GB, Siddiqi N, Beres JA, Logan B, Nagaraja HN, Shidham SG, Piering WF. Clinical risk factors associated with bleeding after native kidney biopsy. Nephrology (Carlton). 2005;10:305–10.CrossRef

99.

Shima N, Sumida K, Kawada M, Sekine A, Yamanouchi M, Hiramatsu R, Hayami N, Hasegawa E, Suwabe T, Hoshino J, Sawa N, Takaichi K, Ohashi K, Fujii T, Ubara Y. Eltrombopag improves refractory thrombocytopenia in a patient with systemic lupus erythematosus. Case Rep Rheumatol. 2018;2018:6305356.PubMedPubMedCentral

100.

Mise K, Ubara Y, Matsumoto M, Sumida K, Hiramatsu R, Hasegawa E, Yamanouchi M, Hayami N, Suwabe T, Hoshino J, Sawa N, Ohashi K, Kokame K, Miyata T, Fujimura Y, Takaichi K. Long term follow up of congenital thrombotic thrombocytopenic purpura (Upshaw–Schulman syndrome) on hemodialysis for 19 years: a case report. BMC Nephrol. 2013;14:156.PubMedPubMedCentralCrossRef

101.

Sekine A, Hasegawa E, Hiramatsu R, Mise K, Sumida K, Ueno T, Yamanouchi M, Hayami N, Suwabe T, Hoshino J, Sawa N, Takaichi K, Ohashi K, Fujii T, Ubara Y. Two types of renovascular lesions in lupus nephritis with clinical thrombotic thrombocytopenic purpura. Case Rep Nephrol Dial. 2015;5:192–9.PubMedPubMedCentralCrossRef

102.

Noda-Narita S, Sumida K, Sekine A, Hoshino J, Mise K, Suwabe T, Hayami N, Yamanouchi M, Ueno T, Mizuno H, Kawada M, Hiramatsu R, Hasegawa E, Sawa N, Takaichi K, Ohashi K, Fujii T, Ubara Y. TAFRO syndrome with refractory thrombocytopenia responding to tocilizumab and romiplostim: a case report. CEN Case Rep. 2018;7:162–8.PubMedPubMedCentralCrossRef

103.

Mizuno H, Sawa N, Watanabe S, Ikuma D, Sekine A, Kawada M, Yamanouchi M, Hasegawa E, Suwabe T, Hoshino J, Takaichi K, Kinowaki K, Fujii T, Ohashi K, Nagata M, Yamaguchi Y, Ubara Y. The clinical and histopathological feature of renal manifestation of TAFRO syndrome. Kidney Int Rep. 2020;5(8):1172–9.PubMedPubMedCentralCrossRef

104.

Simard-Meilleur MC, Troyanov S, Roy L, Dalaire E, Brachemi S. Risk factors and timing of native kidney biopsy complications. Nephron Extra. 2014;4:42–9.PubMedPubMedCentralCrossRef

105.

Piccoli GB, Daidola G, Attini R, Parisi S, Fassio F, Naretto C, Deagostini MC, Castelluccia N, Ferraresi M, Roccatello D, Todros T. Kidney biopsy in pregnancy: evidence for counselling? A systematic narrative review. BJOG. 2013;120:412–27.PubMedCrossRef

106.

Blom K, Odutayo A, Bramham K, Hladunewich MA. Pregnancy and glomerular disease: a systematic review of the literature with management guidelines. Clin J Am Soc Nephrol. 2017;12:1862–72.PubMedPubMedCentralCrossRef

107.

Davison JM, Dunlop W. Renal hemodynamics and tubular function normal human pregnancy. Kidney Int. 1980;18:152–61.PubMedCrossRef

108.

Higby K, Suiter CR, Phelps JY, Siler-Khodr T, Langer O. Normal values of urinary albumin and total protein excretion during pregnancy. Am J Obstet Gynecol. 1994;171:984–9.PubMedCrossRef

109.

Li Y, Wang W, Wang Y, Chen Q. Fetal risks and maternal renal complications in pregnancy with preexisting chronic glomerulonephritis. Med Sci Monit. 2018;24:1008–16.PubMedPubMedCentralCrossRef

110.

Piccoli GB, Cabiddu G, Attini R, Vigotti FN, Maxia S, Lepori N, Tuveri M, Massidda M, Marchi C, Mura S, Coscia A, Biolcati M, Gaglioti P, Nichelatti M, Pibiri L, Chessa G, Pani A, Todros T. Risk of adverse pregnancy outcomes in women with CKD. J Am Soc Nephrol. 2015;26:2011–22.PubMedPubMedCentralCrossRef

111.

Limardo M, Imbasciati E, Ravani P, Surian M, Torres D, Gregorini G, Magistroni R, Casellato D, Gammaro L, Pozzi C, Rene e Gravidanza Collaborative Group of the Italian Society of Nephrology. Pregnancy and progression of IgA nephropathy: results of an Italian multicenter study. Am J Kidney Dis. 2010;56:506–12.PubMedCrossRef

112.

Caritis S, Sibai B, Hauth J, Lindheimer MD, Klebanoff M, Thom E, VanDorsten P, Landon M, Paul R, Miodovnik M, Meis P, Thurnau G. Low-dose aspirin to prevent preeclampsia in women at high risk. National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine Units. N Engl J Med. 1998;338:701–5.PubMedCrossRef

113.

Bujold E, Roberge S, Lacasse Y, Bureau M, Audibert F, Marcoux S, Forest JC, Giguère Y. Prevention of preeclampsia and intrauterine growth restriction with aspirin started in early pregnancy: a meta-analysis. Obstet Gynecol. 2010;116(2 Pt 1):402–14.PubMedCrossRef

114.

Lindheimer MD, Spargo BH, Katz AI. Kidney biopsy in pregnancy-induced hypertension. J Reprod Med. 1975;15:189–94.PubMed

115.

Ochsenbein-Kölble N, Roos M, Gasser T, Huch R, Huch A, Zimmermann R. Cross sectional study of automated blood pressure measurements throughout pregnancy. BJOG. 2004;111:319–25.PubMedCrossRef

116.

Radisic MV, Feldman D, Diaz C, Froment RO. Unexplained hematuria during pregnancy: right-sided nutcracker phenomenon. Int Urol Nephrol. 2007;39:709–11.PubMedCrossRef

117.

Motha MB, Palihawadana TS, Dias TD, Wijesinghe PS. Nutcracker syndrome in pregnancy: a worrying presentation of a benign condition. Ceylon Med J. 2017;62:238–9.PubMedCrossRef

118.

Silverman SG, Gan YU, Mortele KJ, Tuncali K, Cibas ES. Renal masses in the adult patient: the role of percutaneous biopsy. Radiology. 2006;240:6–22.PubMedCrossRef

119.

Smith EH. Complications of percutaneous abdominal fine-needle biopsy. Rev Radiol. 1991;178:253–8.CrossRef

120.

Gordetsky J, Eich ML, Garapati M, Del Pena MCR, Rais-Bahrami S. Active surveillance of small renal masses. Urology. 2019;123:157–66.PubMedCrossRef

121.

Sawa N, Ubara Y, Katori H, Hoshino J, Suwabe T, Tagami T, Takemoto F, Miyakoshi S, Taniguchi S, Ohashi K, Takaichi K. Renal intravascular large B-cell lymphoma localized only within peritubular capillaries. Report of a case. Intern Med. 2007;46:657–62.PubMedCrossRef

122.

Hasegawa J, Hoshino J, Suwabe T, Hayami N, Sumida K, Mise K, Ueno T, Sawa N, Wake A, Ohashi K, Fujii T, Honda K, Takaichi K, Ubara Y. Characteristics of intravascular large B-cell lymphoma limited to the glomerular capillaries: a case report. Case Rep Nephrol Dial. 2015;5:173–9.PubMedPubMedCentralCrossRef

123.

Biondi-Zoccai GG, Lotrionte M, Agostoni P, Abbate A, Fusaro M, Burzotta F, Testa L, Sheiban I, Sangiorgi G. A systematic review and meta-analysis on the hazards of discontinuing or not adhering to aspirin among 50,279 patients at risk for coronary artery disease. Eur Heart J. 2006;27:2667–74.PubMedCrossRef

124.

Lees JS, McQuarrie EP, Mordi N, Geddes CC, Fox JG, Mackinnon B. Risk factors for bleeding complications after nephrologist-performed native kidney biopsy. Clin Kidney J. 2017;10:573–7.PubMedPubMedCentralCrossRef

125.

Fujimoto K, Fujishiro M, Kato M, Higuchi K, Iwakiri R, Sakamoto C, Uchiyama S, Kashiwagi A, Ogawa H, Murakami K, Mine T, Yoshino J, Kinoshita Y, Ichinose M, Matsui T, Japan Gastroenterological Endoscopy Society. Guidelines for gastroenterological endoscopy in patients undergoing antithrombotic treatment. Dig Endosc. 2014;26(1):1–14.PubMedCrossRef

126.

Fernandez Lynch H, Joffe S, Feldman EA. Informed consent and the role of the treating physician. N Engl J Med. 2018;378:2433–8.PubMedCrossRef

127.

Whittier WL, Korbet SM. Timing of complications in percutaneous kidney biopsy. J Am Soc Nephrol. 2004;15:142–7.PubMedCrossRef

128.

Lin WC, Yang Y, Wen YK, Chang CC. Outpatient versus inpatient kidney biopsy: a retrospective study. Clin Nephrol. 2006;66:17–24.PubMedCrossRef

129.

Bairy M, Beleed K, Webb AT, Bhandari S. Safety of outpatient kidney biopsy: one center’s experience with 178 native kidney biopsies. Am J Kidney Dis. 2008;52:631–2.PubMedCrossRef

130.

Roccatello D, Sciascia S, Rossi D, Naretto C, Bazzan M, Solfietti L, Baldovino S, Menegatti E. Outpatient percutaneous native kidney biopsy: safety profile in a large monocentric cohort. BMJ Open. 2017;7:e015243.PubMedPubMedCentralCrossRef

131.

Šimunov B, Gunjača M, Čingel B, Škegro D, Knotek M. Safety of outpatient kidney biopsies. Nephron. 2018;138:275–9.PubMedCrossRef

132.

Kajawo S, Moloi MW, Noubiap JJ, Ekrikpo U, Kengne AP, Okpechi IG. Incidence of major complications after percutaneous native renal biopsies in adults from low-income to middle-income countries: a protocol for systematic review and meta-analysis. BMJ Open. 2018;8(4):e020891.PubMedPubMedCentralCrossRef

133.

Iversen P, Brun C. Aspiration biopsy of the kidney, 1951. J Am Soc Nephrol. 1997;8(11):1778–87 (discussion 1778-86).PubMedCrossRef

134.

Schorr M, Roshanov PS, Weir MA, House AA. Frequency, timing, and prediction of major bleeding complications from percutaneous kidney biopsy. Can J Kidney Health Dis. 2020;25(7):2054358120923527.

135.

Korbet SM. Nephrology and the percutaneous kidney biopsy: a procedure in jeopardy of being lost along the way. Clin J Am Soc Nephrol. 2012;7:1545–7.PubMedCrossRef

136.

Kark RM, Muehrcke RC. Biopsy of kidney in prone position. Lancet. 1954;266:1047–9.PubMedCrossRef

137.

Kark RM, Muehrcke RC, Pollak VE, Kiefer JH. An analysis of five hundred percutaneous renal biopsies. AMA Arch Intern Med. 1958;101:439–51.PubMedCrossRef

138.

Madaio MP. kidney biopsy. Kidney Int. 1990;38:529–43.PubMedCrossRef

139.

Donovan KL, Thomas DM, Wheeler DC, Macdougall IC, Williams JD. Experience with a new method for percutaneous kidney biopsy. Nephrol Dial Transplant. 1991;6:731–3.PubMedCrossRef

140.

Bataille S, Jourde N, Daniel L, Mondain JR, Faure M, Gobert P, Alcheikh-Hassan Z, Lankester M, Giaime P, Gaudart J, Dussol B, Berland Y, Burtey S. Comparative safety and efficiency of five percutaneous kidney biopsy approaches of native kidneys: a multicenter study. Am J Nephrol. 2012;35:387–93.PubMedCrossRef

141.

Tuladhar AS, Shrestha A, Pradhan S, Manandhar DN, Chhetri Poudyal PK, Rijal A, Poudel P, Maskey A, Bhoomi KK. USG assisted and USG guided percutaneous kidney biopsy at Nepal Medical College Teaching Hospital: a three and half years study. Nepal Med Coll J. 2014;16:26–9.PubMed

142.

Rao NS, Chandra A. Needle guides enhance tissue adequacy and safety of ultrasound-guided renal biopsies. Kidney Res Clin Pract. 2018;37:41–8.PubMedPubMedCentralCrossRef

143.

Shamshirgar F, Bagheri SM. Percutaneous ultrasound-guided kidney biopsy; a comparison of axial vs. sagittal probe location. Rom J Intern Med. 2017;55:96–102.PubMed

144.

Bandari J, Fuller TW, Turner Ii RM, D’Agostino LA. Kidney biopsy for medical renal disease: indications and contraindications. Can J Urol. 2016b;23(1):8121–6.PubMed

145.

Stec AA, Stratton KL, Kaufman MR, Chang SS, Milam DF, Herrell SD, Dmochowski RR, Smith JA Jr, Clark PE, Cookson MS. Open Kidney biopsy: comorbidities and complications in a contemporary series. BJU Int. 2010;106(1):102–6.PubMedCrossRef

146.

Shetye KR, Kavoussi LR, Ramakumar S, Fugita OE, Jarrett TW. Laparoscopic Kidney biopsy: a 9-year experience. BJU Int. 2003;91(9):817–20.PubMedCrossRef

147.

Furness PN, Philpott CM, Chorbadjian MT, Nicholson ML, Bosmans JL, Corthouts BL, Bogers JJ, Schwarz A, Gwinner W, Haller H, Mengel M, Seron D, Moreso F, Cañas C. Protocol biopsy of the stable renal transplant: a multicenter study of methods and complication. Transplantation. 2003;76:969–73.PubMedCrossRef

148.

Schwarz A, Gwinner W, Hiss M, Radermacher J, Mengel M, Haller H. Safety and adequacy of renal transplant protocol biopsies. Am J Transplant. 2005;5:1992–6.PubMedCrossRef

149.

Danovitch GM, editor. Handbook of kidney transplantation. 5th ed. Philadelphia: Lippincott Williams & Wilkins; 2010.

150.

Korbet SM. Percutaneous Kidney biopsy. Semin Nephrol. 2002;22:254–67.PubMedCrossRef

151.

Burstein DM, Schwartz MM, Korbet SM. Percutaneous Kidney biopsy with the use of real-time ultrasound. Am J Nephrol. 1991;11:195–200.PubMedCrossRef

152.

Marwah DS, Korbet SM. Timing of complications in percutaneous Kidney biopsy: what is the optimal period of observation? Am J Kidney Dis. 1996;28:47–52.PubMedCrossRef

153.

Mendelssohn DC, Cole EH. Outcomes of percutaneous kidney biopsy, including those of solitary native kidneys. Am J Kidney Dis. 1995;26:580–5.PubMedCrossRef

154.

Kim D, Kim H, Shin G, Ku S, Ma K, Shin S, Gi H, Lee E, Yim H. A randomized, prospective, comparative study of manual and automated renal biopsies. Am J Kidney Dis. 1998;32:426–31.PubMedCrossRef

155.

Nass K, O’Neill WC. Bedside Kidney biopsy: ultrasound guidance by the nephrologist. Am J Kidney Dis. 1999;34:955–9.PubMedCrossRef

156.

Eiro M, Katoh T, Watanabe T. Risk factors for bleeding complications in percutaneous Kidney biopsy. Clin Exp Nephrol. 2005;9:40–5.PubMedCrossRef

157.

Manno C, Strippoli GF, Arnesano L, Bonifati C, Campobasso N, Gesualdo L, Schena FP. Predictors of bleeding complications in percutaneous ultrasound-guided Kidney biopsy. Kidney Int. 2004;66:1570–7.PubMedCrossRef

158.

Fraser IR, Fairley KF. Kidney biopsy as an outpatient procedure. Am J Kidney Dis. 1995;25:876–8.PubMedCrossRef

159.

Jones B, Puvaneswary M, Nanra R, Trevillian P, Carney S, Gillies A. Reduced duration of bed rest after percutaneous Kidney biopsy. Clin Nephrol. 1991;35:44–5.PubMed

160.

Simckes AM, Blowey DL, Gyves KM, Alon US. Success and safety of same-day kidney biopsy in children and adolescents. Pediatr Nephrol. 2000;14:946–52.PubMedCrossRef

161.

Takeuchi Y, Ojima Y, Kagaya S, Aoki S, Nagasawa T. Manual compression and reflex syncope in native Kidney biopsy. Clin Exp Nephrol. 2018;22:1100–7.PubMedPubMedCentralCrossRef

162.

Ishikawa E, Nomura S, Obe T, Katayama K, Oosugi K, Murata T, Tanoue A, Fujimoto M, Matsuo H, Ito M. How long is strict bed rest necessary after Kidney biopsy? Clin Exp Nephrol. 2009;13:594–7.PubMedCrossRef

163.

Manno C, Bonifati C, Torres DD, Campobasso N, Schena FP. Desmopressin acetate in percutaneous ultrasound-guided kidney biopsy: a randomized controlled trial. Am J Kidney Dis. 2011;57:850–5.PubMedCrossRef

164.

Khajehdehi P, Junaid SM, Salinas-Madrigal L, Schmitz PG, Bastani B. Percutaneous Kidney biopsy in the 1990s: safety, value, and implications for early hospital discharge. Am J Kidney Dis. 1999;34:92–7.PubMedCrossRef

165.

Rasmussen LR, Loft M, Nielsen TK, Bjødstrup Jensen M, Høyer S, Hørlyck A, Graumann O. Short-term complications for percutaneous ultrasound-guided biopsy of renal masses in adult outpatients. Acta Radiol. 2018;59(4):491–6.PubMedCrossRef

166.

Renal Physicians Association. RPA position on optimal length of observation after percutaneous Kidney biopsy. Clin Nephrol. 2001;56:179–80.

167.

Waldo BD, Grabau ZJ, Mengistu TM, Crow WT. The value of post-biopsy ultrasound in predicting complications after percutaneous Kidney biopsy of native kidneys. Nephrol Dial Transplant. 2009;24:2433–9.PubMedCrossRef

168.

Ishikawa E, Nomura S, Hamaguchi T, Obe T, Inoue-Kiyohara M, Oosugi K, Katayama K, Ito M. Ultrasonography as a predictor of overt bleeding after Kidney biopsy. Clin Exp Nephrol. 2009;13:325–31.PubMedCrossRef

169.

Brachemi S, Bollée G. Kidney biopsy practice: what is the gold standard? World J Nephrol. 2014;3:287–94.PubMedPubMedCentralCrossRef

170.

Franke M, Kramarczyk A, Taylan C, Maintz D, Hoppe B, Koerber F. Ultrasound-guided percutaneous Kidney biopsy in 295 children and adolescents: role of ultrasound and analysis of complications. PLoS ONE. 2014;9(12):e114737.PubMedPubMedCentralCrossRef

171.

Xu DM, Chen M, Zhou FD, Zhao MH. Risk factors for severe bleeding complications in percutaneous Kidney biopsy. Am J Med Sci. 2017;353(3):230–5.PubMedCrossRef

172.

Yamamoto H, Hashimoto H, Nakamura M, Horiguchi H, Yasunaga H. Relationship between hospital volume and hemorrhagic complication after percutaneous Kidney biopsy: results from the Japanese diagnosis procedure combination database. Clin Exp Nephrol. 2015;19:271–7.PubMedCrossRef

173.

Tanaka K, Kitagawa M, Onishi A, Yamanari T, Ogawa-Akiyama A, Mise K, Inoue T, Morinaga H, Uchida HA, Sugiyama H, Wada J. Arterial stiffness is an independent risk factor for anemia after percutaneous native kidney biopsy. Kidney Blood Press Res. 2017;42:284–93.PubMedCrossRef

174.

Chikamatsu Y, Matsuda K, Takeuchi Y, Kagaya S, Ojima Y, Fukami H, Sato H, Saito A, Iwakura Y, Nagasawa T. Quantification of bleeding volume using computed tomography and clinical complications after percutaneous Kidney biopsy. Clin Kidney J. 2017;10:9–15.PubMedPubMedCentralCrossRef

175.

Mejía-Vilet JM, Márquez-Martínez MA, Cordova-Sanchez BM, Ibargüengoitia MC, Correa-Rotter R, Morales-Buenrostro LE. Simple risk score for prediction of hemorrhagic complications after a percutaneous Kidney biopsy. Nephrology (Carlton). 2018b;23:523–9.CrossRef

176.

Palsson R, Short SAP, Kibbelaar ZA, Amodu A, Stillman IE, Rennke HG, McMahon GM, Waikar SS. Bleeding complications after percutaneous native kidney biopsy: results from the Boston kidney biopsy cohort. Kidney Int Rep. 2020;5(4):511–8.PubMedPubMedCentralCrossRef

177.

Chen TK, Estrella MM, Fine DM. Predictors of kidney biopsy complication among patients with systemic lupus erythematosus. Lupus. 2012;21:848–54.PubMedPubMedCentralCrossRef

178.

Fish R, Pinney J, Jain P, Addison C, Jones C, Jayawardene S, Booth J, Howie AJ, Ghonemy T, Rajabali S, Roberts D, White L, Khan S, Morgan M, Cockwell P, Hutchison CA. The incidence of major hemorrhagic complications after renal biopsies in patients with monoclonal gammopathies. Clin J Am Soc Nephrol. 2010;5:1977–80.PubMedPubMedCentralCrossRef

179.

Altindal M, Yildirim T, Turkmen E, Unal M, Boga I, Yilmaz R, Arici M, Altun B, Erdem Y. Safety of percutaneous ultrasound-guided kidney biopsy in patients with AA amyloidosis. Nephron. 2015;131:17–22.PubMedCrossRef

180.

Ali H, Murtaza A, Anderton J, Ahmed A. Post Kidney biopsy complication rate and diagnostic yield comparing hands free (ultrasound-assisted) and ultrasound-guided biopsy techniques of renal allografts and native kidneys. Springerplus. 2015;4:491.PubMedPubMedCentralCrossRef

181.

Mai J, Yong J, Dixson H, Makris A, Aravindan A, Suranyi MG, Wong J. Is bigger better? A retrospective analysis of native renal biopsies with 16 Gauge versus 18 Gauge automatic needles. Nephrology (Carlton). 2013;18:525–30.CrossRef

182.

Antunes PRB, Prado FFM, de Souza FTA, de Siqueira EC, de Campos MÁ, Álvares MCB, Neto RB. Clinical complications in Kidney biopsy using two different needle gauges: the impact of large hematomas, a random clinical trial study. Int J Urol. 2018;25:544–8.PubMedCrossRef

183.

Prasad N, Kumar S, Manjunath R, Bhadauria D, Kaul A, Sharma RK, Gupta A, Lal H, Jain M, Agrawal V. Real-time ultrasound-guided percutaneous Kidney biopsy with needle guide by nephrologists decreases post-biopsy complications. Clin Kidney J. 2015;8:151–6.PubMedPubMedCentralCrossRef

184.

Torres Muñoz A, Valdez-Ortiz R, González-Parra C, Espinoza-Dávila E, Morales-Buenrostro LE, Correa-Rotter R. Percutaneous Kidney biopsy of native kidneys: efficiency, safety and risk factors associated with major complications. Arch Med Sci. 2011;7:823–31.PubMedPubMedCentralCrossRef

185.

Lubas A, Wojtecka A, Smoszna J, Koziński P, Frankowska E, Niemczyk S. Hemodynamic characteristics and the occurrence of Kidney biopsy-related arteriovenous fistulas in native kidneys. Int Urol Nephrol. 2016;48:1667–73.PubMedPubMedCentralCrossRef

186.

Meng CH, Elkin M. Immediate angiographic manifestations of iatrogenic renal injury due to percutaneous needle biopsy. Radiology. 1971;100:335–41.PubMedCrossRef

187.

Stiles KP, Yuan CM, Chung EM, Lyon RD, Lane JD, Abbott KC. Kidney biopsy in high-risk patients with medical diseases of the kidney. Am J Kidney Dis. 2000;36:419–33.PubMedCrossRef

188.

Gülcü A, Göktay Y, Soylu A, Türkmen M, Kavukçu S, Seçil M, Karabay N. Doppler US evaluation of Kidney biopsy complications in children. Diagn Interv Radiol. 2013;19:15–9.PubMed

189.

Buczek M, Popiela TJ, Urbanik A. Pseudoaneurysma as iatrogenic complication of Kidney biopsy: management by transcatheter embolization. Przegl Lek. 2012;69:357–9.PubMed

190.

Ito T, Ishikawa E, Ito M. Lumbar artery injury following Kidney biopsy. Clin Exp Nephrol. 2016;20:145–6.PubMedCrossRef

191.

Krejčí K, Černá M, Žamboch K, Orság J, Klíčová A, Zadražil J. Late rupture of lumbar artery as an unusual complication after Kidney biopsy: case report. Urol Int. 2017;98:112–4.PubMedCrossRef

192.

Ono A, Inoue T, Tomori K, Okada H. Page kidney following Kidney biopsy. Intern Med. 2017;56:875.PubMedPubMedCentralCrossRef

193.

Ham YR, Moon KR, Bae HJ, Ju HJ, Jang WI, Choi DE, Na KR, Lee KW, Shin YT. A case of urine leakage: an unusual complication after Kidney biopsy. Chonnam Med J. 2011;47:181–4.PubMedPubMedCentralCrossRef

194.

Whittier WL, Sayeed K, Korbet SM. Clinical factors influencing the decision to transfuse after percutaneous native kidney biopsy. Clin Kidney J. 2016;9:102–7.PubMedCrossRef

195.

Alotaibi M, Shrouder-Henry J, Amaral J, Parra D, Temple M, John P, Connolly B. The positive color Doppler sign post biopsy: effectiveness of US-directed compression in achieving hemostasis. Pediatr Radiol. 2011;41:362–8.PubMedCrossRef

196.

Hu T, Liu Q, Xu Q, Liu H, Feng Y, Qiu W, Huang F, Lv Y. Absorption fever characteristics due to percutaneous Kidney biopsy-related hematoma. Medicine. 2016;95:e4754.PubMedPubMedCentralCrossRef

197.

Shima N, Hayami N, Mizuno H, Kawada M, Sekine A, Sumida K, Hiramatsu R, Yamanouchi M, Hasegawa E, Suwabe T, Hoshino J, Sawa N, Takaichi K, Ohashi K, Fujii T, Minota S, Ubara Y. Arteriovenous fistula-related renal bleeding 5 days after percutaneous Kidney biopsy. CEN Case Rep. 2019;8(4):280–4.PubMedPubMedCentralCrossRef

198.

Solez K, Axelsen RA, Benediktsson H, Burdick JF, Cohen AH, Colvin RB, Croker BP, Droz D, Dunnill MS, Halloran PF, et al. International standardization of criteria for the histologic diagnosis of renal allograft rejection: the Banff working classification of kidney transplant pathology. Kidney Int. 1993;44:411–22.PubMedCrossRef

199.

Corwin HL, Schwartz MM, Lewis EJ. The importance of sample size in the interpretation of the Kidney biopsy. Am J Nephrol. 1988;8:85–9.PubMedCrossRef

200.

Wang HJ, Kjellstrand CM, Cockfield SM, Solez K. On the influence of sample size on the prognostic accuracy and reproducibility of renal transplant biopsy. Nephrol Dial Transplant. 1998;13:165–72.PubMedCrossRef

201.

Luciano RL, Moeckel GW. Update on the native kidney biopsy: core curriculum 2019. Am J Kidney Dis. 2019;73:404–15.PubMedCrossRef

202.

Nasr SH, Galgano SJ, Markowitz GS, Stokes MB, D’Agati VD. Immunofluorescence on pronase-digested paraffin sections: a valuable salvage technique for renal biopsies. Kidney Int. 2006;70:2148–51.PubMedCrossRef

203.

Deshpande V, Zen Y, Chan JK, Yi EE, Sato Y, Yoshino T, Klöppel G, Heathcote JG, Khosroshahi A, Ferry JA, Aalberse RC, Bloch DB, Brugge WR, Bateman AC, Carruthers MN, Chari ST, Cheuk W, Cornell LD, Fernandez-Del Castillo C, Forcione DG, Hamilos DL, Kamisawa T, Kasashima S, Kawa S, Kawano M, Lauwers GY, Masaki Y, Nakanuma Y, Notohara K, Okazaki K, Ryu JK, Saeki T, Sahani DV, Smyrk TC, Stone JR, Takahira M, Webster GJ, Yamamoto M, Zamboni G, Umehara H, Stone JH. Consensus statement on the pathology of IgG4-related disease. Mod Pathol. 2012;25:1181–92.PubMedCrossRef

204.

Vernier RL, Farquhar MG, Brunson JG, Good RA. Chronic renal disease in children; correlation of clinical findings with morphologic characteristics seen by light and electron microscopy. AMA J Dis Child. 1958;96:306–43.PubMedCrossRef

205.

Vehaskari VM, Rapola J, Koskimies O, Savilahti E, Vilska J, Hallman N. Microscopic hematuria in school children: epidemiology and clinicopathologic evaluation. J Pediatr. 1979;95:676–84.PubMedCrossRef

206.

Takei S, Maeno N, Shigemori M, Imanaka H, Mori H, Nerome Y, Kanekura S, Takezaki T, Hokonohara M, Miyata K, Fujikawa S. Clinical features of Japanese children and adolescents with systemic lupus erythematosus: results of 1980–1994 survey. Acta Pediatr Jpn. 1997;39:250–6.CrossRef

207.

Wakiguchi H, Takei S, Kubota T, Miyazono A, Kawano Y. Treatable renal disease in children with silent lupus nephritis detected by baseline biopsy: association with serum C3 levels. Clin Rheumatol. 2017;36:433–7.PubMedCrossRef

208.

Ito S, Ogura M, Kamei K, Matsuoka K, Warnock DG. Significant improvement in Fabry disease podocytopathy after 3 years of treatment with agalsidase beta. Pediatr Nephrol. 2016;31:1369–73.PubMedCrossRef

209.

Najafian B, Mauer M, Hopkin RJ, Svarstad E. Renal complications of Fabry disease in children. Pediatr Nephrol. 2013;28:679–87.PubMedCrossRef

210.

Emma F, Bertini E, Salviati L, Montini G. Renal involvement in mitochondrial cytopathies. Pediatr Nephrol. 2012;27:539–50.PubMedCrossRef

211.

Nozu K, Nakanishi K, Abe Y, Udagawa T, Okada S, Okamoto T, Kaito H, Kanemoto K, Kobayashi A, Tanaka E, Tanaka K, Hama T, Fujimaru R, Miwa S, Yamamura T, Yamamura N, Horinouchi T, Minamikawa S, Nagata M, Iijima K. A review of clinical characteristics and genetic backgrounds in Alport syndrome. Clin Exp Nephrol. 2019;23(2):158–68.PubMedCrossRef

212.

Kamiyoshi N, Nozu K, Fu XJ, Morisada N, Nozu Y, Ye MJ, Imafuku A, Miura K, Yamamura T, Minamikawa S, Shono A, Ninchoji T, Morioka I, Nakanishi K, Yoshikawa N, Kaito H, Iijima K. Genetic, clinical, and pathologic backgrounds of patients with autosomal dominant Alport syndrome. Clin J Am Soc Nephrol. 2016;11(8):1441–9.PubMedPubMedCentralCrossRef

213.

Horinouchi T, Nozu K, Yamamura T, Minamikawa S, Omori T, Nakanishi K, Fujimura J, Ashida A, Kitamura M, Kawano M, Shimabukuro W, Kitabayashi C, Imafuku A, Tamagaki K, Kamei K, Okamoto K, Fujinaga S, Oka M, Igarashi T, Miyazono A, Sawanobori E, Fujimaru R, Nakanishi K, Shima Y, Matsuo M, Ye MJ, Nozu Y, Morisada N, Kaito H, Iijima K. Detection of splicing abnormalities and genotype-phenotype correlation in X-linked Alport syndrome. J Am Soc Nephrol. 2018;29(8):2244–54.PubMedPubMedCentralCrossRef

214.

Greenbaum LA, Simckes AM, McKenney D, Kainer G, Nagaraj SK, Trachtman H, Alon US. Pediatric biopsy of a single native kidney. Pediatr Nephrol. 2000;15:66–9.PubMedCrossRef

215.

Kang S, Yoon HS, Lee EH. Should healthy children who will undergo minor surgery be screened for coagulation disorder? Pediatr Hematol Oncol. 2016;33:233–8.PubMedCrossRef

216.

Guay J, Faraoni D, Bonhomme F, Borel Derlon A, Lasne D. Ability of hemostatic assessment to detect bleeding disorders and to predict abnormal surgical blood loss in children: a systematic review and meta-analysis. Paediatr Anaesth. 2015;25:1216–26.PubMedCrossRef

217.

Bhasin N, Parker RI. Diagnostic outcome of preoperative coagulation testing in children. Pediatr Hematol Oncol. 2014;31:458–66.PubMedCrossRef

218.

Samková A, Blatný J, Fiamoli V, Dulíček P, Pařízková E. Significance and causes of abnormal preoperative coagulation test results in children. Haemophilia. 2012;18:e297-301.PubMedCrossRef

219.

Estcourt LJ, Malouf R, Doree C, Trivella M, Hopewell S, Birchall J. Prophylactic platelet transfusions prior to surgery for people with a low platelet count. Cochrane Database Syst Rev. 2018;9:CD012779.PubMed

220.

Varnell CD Jr, Stone HK, Welge JA. Bleeding complications after pediatric kidney biopsy: a systematic review and meta-analysis. Clin J Am Soc Nephrol. 2019;14:57–65.PubMedCrossRef

221.

Zhu MS, Chen JZ, Xu AP. Factors that can minimize bleeding compli-cations after Kidney biopsy. Int Urol Nephrol. 2014;46:1969–75.PubMedPubMedCentralCrossRef

222.

Rianthavorn P, Kerr SJ, Chiengthong K. Safety of paediatric percutaneous native kidney biopsy and factors predicting bleeding complications. Nephrology (Carlton). 2014;19:143–8.CrossRef

223.

Vidhun J, Masciandro J, Varich L, Salvatierra O Jr, Sarwal M. Safety and risk stratification of percutaneous biopsies of adult-sized renal allografts in infant and older pediatric recipients. Transplantation. 2003;76(3):552–7.PubMedCrossRef

224.

Kark RM. The development of percutaneous Kidney biopsy in man. Am J Kidney Dis. 1990;16:585–9.PubMedCrossRef

225.

Pokhrel A, Agrawal RK, Baral A, Rajbhandari A, Hada R. Percutaneous Kidney biopsy: comparison of blind and real-time ultrasound-guided technique. J Nepal Health Res Counc. 2018;16(1):66–72.PubMedCrossRef

226.

Lindgren PG. Ultrasonically guided punctures. A modified technique. Radiology. 1980;137:235–7.PubMedCrossRef

227.

Chunduri S, Whittier WL, Korbet SM. Adequacy and complication rates with 14- vs. 16-gauge automated needles in percutaneous Kidney biopsy of native kidneys. Semin Dial. 2015;28:E11-14.PubMedCrossRef

228.

Øvrehus MA, Oldereid TS, Dadfar A, Bjørneklett R, Aasarød KI, Fogo AB, Ix JH, Hallan SI. Clinical phenotypes and long-term prognosis in white patients with biopsy-verified hypertensive nephrosclerosis. Kidney Int Rep. 2019;5(3):339–47.PubMedPubMedCentralCrossRef

229.

Sethi I, Brier M, Dwyer A. Predicting post Kidney biopsy complications. Semin Dial. 2013;26(5):633–5.PubMedCrossRef

230.

White RH, Poole C. Day care Kidney biopsy. Pediatr Nephrol. 1996;10:408–11.PubMedCrossRef

231.

Davis ID, Oehlenschlager W, O’Riordan MA, Avner ED. Pediatric Kidney biopsy: should this procedure be performed in an outpatient setting? Pediatr Nephrol. 1998;12:96–100.PubMedCrossRef

232.

Sinha MD, Lewis MA, Bradbury MG, Webb NJ. Percutaneous real-time ultrasound-guided Kidney biopsy by automated biopsy gun in children: safety and complications. J Nephrol. 2006;19(1):41–4.PubMed

233.

Hussain F, Watson AR, Hayes J, Evans J. Standards for renal biopsies: comparison of inpatient and day care procedures. Pediatr Nephrol. 2003;18:53–6.PubMedCrossRef

234.

Murphy MS. Sedation for invasive procedures in pediatrics. Arch Dis Child. 1997;77:281–4.PubMedPubMedCentralCrossRef

235.

Reich DL, Silvay G. Ketamine: an update on the first twenty-five years of clinical experience. Can J Anaesth. 1989;36:186–97.PubMedCrossRef

236.

Green SM, Johnson NE. Ketamine sedation for pediatric procedures: part 2, review and implications. Ann Emerg Med. 1990;19:1033–46.PubMedCrossRef

237.

Mikhael MS, Wray S, Robb ND. Intravenous conscious sedation in children for outpatient dentistry. Br Dent J. 2007;203:323–31.PubMedCrossRef

238.

Di Liddo L, D’Angelo A, Nguyen B, Bailey B, Amre D, Stanciu C. Etomidate versus midazolam for procedural sedation in pediatric outpatients: a randomized controlled trial. Ann Emerg Med. 2006;48:433–40.PubMedCrossRef

239.

Cravero JP, Beach ML, Blike GT, Gallagher SM, Hertzog JH, Pediatric Sedation Research Consortium. The incidence and nature of adverse events during pediatric sedation/anesthesia with propofol for procedures outside the operating room: a report from the Pediatric Sedation Research Consortium. Anesth Analg. 2009;108:795–804.PubMedCrossRef

240.

Kamat PP, McCracken CE, Gillespie SE, Fortenberry JD, Stockwell JA, Cravero JP, Hebbar KB. Pediatric critical care physician-administered procedural sedation using propofol: a report from the Pediatric Sedation Research Consortium Database. Pediatr Crit Care Med. 2015;16:11–20.PubMedCrossRef

241.

Mallory MD, Baxter AL, Yanosky DJ, Cravero JP, Pediatric Sedation Research Consortium. Emergency physician-administered propofol sedation: a report on 25,433 sedations from the pediatric sedation research consortium. Ann Emerg Med. 2011;57:462–8 (e1).PubMedCrossRef

242.

Mourani CC, Antakly MC, Haddad-Zebouni S. Pediatric Kidney biopsy: ambulatory versus overnight hospitalization. J Med Liban. 2001;49(6):316–8.PubMed

243.

Hussain F, Mallik M, Marks SD, Watson AR, British Association of Paediatric Nephrology. Renal biopsies in children: current practice and audit of outcomes. Nephrol Dial Transplant. 2010;25:485–9.PubMedCrossRef

244.

Gupta A, Campion-Smith J, Hayes W, Deal JE, Gilbert RD, Inward C, Judd BA, Krishnan RG, Marks SD, O’Brien C, Shenoy M, Sinha MD, Tse Y, Tyerman K, Mallik M, Hussain F, British Association for Paediatric Nephrology. Positive trends in paediatric Kidney biopsy service provision in the UK: a national survey and re-audit of paediatric Kidney biopsy practice. Pediatr Nephrol. 2016;31:613–21.PubMedCrossRef

245.

Muthusami P, Sunder S, Gallibois C, Kitamura E, Parra D, Amaral J, John P, Noone D, Connolly B. Measuring hemoglobin prior to early discharge without routine surveillance ultrasound after percutaneous native Kidney biopsy in children. Pediatr Nephrol. 2017;32:1927–34.PubMedCrossRef

246.

Gagnon MH, Lin MF, Lancia S, Salter A, Yano M. A color flow tract in ultrasound-guided random renal core biopsy predicts complications. J Ultrasound Med. 2020;39(7):1335–42.PubMedCrossRef

247.

Ding JJ, Lin SH, Huang JL, Wu TW, Hsia SH, Lin JJ, Chou YC, Tseng MH. Risk factors for complications of percutaneous ultrasound-guided Kidney biopsy in children. Pediatr Nephrol. 2020;35(2):271–8.PubMedCrossRef

248.

Isiyel E, Fidan K, Buyukkaragoz B, Akcaboy M, Kandur Y, Gonul II, Buyan N, Bakkaloglu S, Soylemezoglu O. Results of native and transplant kidney biopsies of children in a single center over a 15 years period. Ren Fail. 2017;39(1):702–6.PubMedPubMedCentralCrossRef

249.

Hunsicker LG, Bennett LE. Design of trials of methods to reduce late renal allograft loss: the price of success. Kidney Int (Suppl). 1995;52:S120-123.

250.

Wilkinson A. Protocol transplant biopsies: are they really needed? Clin J Am Soc Nephrol. 2006;1(1):130–7.PubMedCrossRef

251.

Birk PE, Blydt-Hansen TD, Dart AB, Kaita LM, Proulx C, Taylor G. Low incidence of adverse events in outpatient pediatric renal allograft biopsies. Pediatr Transplant. 2007;11(2):196–200.PubMedCrossRef

Titel: Kidney biopsy guidebook 2020 in Japan
verfasst von: Yoshifumi Ubara
Takehiko Kawaguchi
Tasuku Nagasawa
Kenichiro Miura
Takayuki Katsuno
Takashi Morikawa
Eiji Ishikawa
Masao Ogura
Hideki Matsumura
Ryota Kurayama
Shinsuke Matsumoto
Yuhji Marui
Shigeo Hara
Shoichi Maruyama
Ichiei Narita
Hirokazu Okada
Kazuhiko Tsuruya
Committee of Practical Guide for Kidney Biopsy 2020
Publikationsdatum: 19.02.2021
Verlag: Springer Singapore
Erschienen in: Clinical and Experimental Nephrology / Ausgabe 4/2021
Print ISSN: 1342-1751
Elektronische ISSN: 1437-7799
DOI: https://doi.org/10.1007/s10157-020-01986-6

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Kidney biopsy guidebook 2020 in Japan

Publisher's Note

Overview

Chapter 1: Indication for kidney biopsy (Table 2)

Chapter 2: Kidney biopsy for patients with a clinical condition of high risk for percutaneous native kidney biopsy

Overview

Overview

Explanation document to the patients

Chapter 4: Pre-biopsy evaluation

Chapter 5. Method of kidney biopsy (technique)

Chapter 6: After care of the biopsy and post procedure observation

Chapter 7: Complications

Chapter 8: Histological evaluation of kidney biopsy specimen

Chapter 9: Kidney biopsy in children

Indication of kidney biopsy (Table 6)

Kidney biopsy for clinical condition with high risk

Pre-biopsy evaluation

Method of kidney biopsy (technique)

Sedation

After care of the biopsy and post procedure observation

Complications

Chapter 10: Biopsy of transplanted kidney

Chapter 11: Open (surgical) kidney biopsy and laparoscopic kidney biopsy

Acknowledgements

Compliance with ethical standards

Conflict of interest

Publisher's Note

Unsere Produktempfehlungen

e.Med Interdisziplinär

e.Med Allgemeinmedizin

e.Med Innere Medizin

e.Med Urologie

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Gibt es eine Wende bei den bioresorbierbaren Gefäßstützen?

Triglyzeridsenker schützt nicht nur Hochrisikopatienten

Vorsicht, erhöhte Blutungsgefahr nach PCI!

Erhöhte Mortalität bei postpartalem Brustkrebs

Update Innere Medizin

Springer Medizin

Publisher's Note

Overview

Chapter 1: Indication for kidney biopsy (Table 2)

Chapter 2: Kidney biopsy for patients with a clinical condition of high risk for percutaneous native kidney biopsy

Overview

Chapter 3: Informed consent and explanation document to the patients

Informed consent in kidney biopsy

Overview

Explanation document to the patients

Chapter 4: Pre-biopsy evaluation

Chapter 5. Method of kidney biopsy (technique)

Chapter 6: After care of the biopsy and post procedure observation

Chapter 7: Complications

Chapter 8: Histological evaluation of kidney biopsy specimen

Chapter 9: Kidney biopsy in children

Indication of kidney biopsy (Table 6)

Kidney biopsy for clinical condition with high risk

Pre-biopsy evaluation

Informed consent for kidney biopsy, explanation about kidney biopsy

Method of kidney biopsy (technique)

Sedation

After care of the biopsy and post procedure observation

Complications

Chapter 10: Biopsy of transplanted kidney

Chapter 11: Open (surgical) kidney biopsy and laparoscopic kidney biopsy

Acknowledgements

Compliance with ethical standards

Conflict of interest

Publisher's Note

Unsere Produktempfehlungen

e.Med Interdisziplinär

e.Med Allgemeinmedizin

e.Med Innere Medizin

e.Med Urologie

Weitere Artikel der Ausgabe 4/2021

Clinical characteristics of patients with early relapse during B-cell depletion after rituximab treatment for complicated steroid-dependent nephrotic syndrome

Correction to: Validation of the diagnostic criteria for IgG4‑related kidney disease (IgG4‑RKD) 2011, and proposal of a new 2020 version

Safety and utility of the alpha-replacer for treatment of intraluminal obstruction of peritoneal catheters by fibrin clots

Relationship between serum lipid concentrations and impaired renal function in patients with chronic kidney disease: the Fukuoka Kidney Disease Registry Study

Impact of water consumption on renal function in the general population: a cross-sectional analysis of KNHANES data (2008–2017)

Hypokalemia in Patients with COVID-19

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Gibt es eine Wende bei den bioresorbierbaren Gefäßstützen?

Triglyzeridsenker schützt nicht nur Hochrisikopatienten

Vorsicht, erhöhte Blutungsgefahr nach PCI!

Erhöhte Mortalität bei postpartalem Brustkrebs

Update Innere Medizin